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ABSTRACT 
 
 
Obese people with insulin resistance are at high risk of developing 
disease-related complications like heart attack and stroke.  Recently, a significant 
amount of data has been published linking chronic inflammation with obesity and 
the etiology of the Metabolic syndrome (MetS).  Scientists have found many of 
the same inflammatory pathways and pro-inflammatory molecules are involved in 
both conditions.  In particular, recent studies have elucidated an important role 
for the inflammasome in the etiology of these diseases. Interfering with these 
chronic inflammatory processes may provide a new way to treat obesity.  Pilot 
studies in animals and humans have shown positive outcomes using anti-
inflammatory drugs for treatment of both obesity and MetS.  One advantage to 
using anti-inflammatory drugs is that many are already clinically approved with 
known risk/benefit profiles. Trials to test their efficacy in MetS and obesity are 
thus feasible.  If proven beneficial, these drugs could help treat a huge number of 
patients who do not currently have other safe options. In this thesis I propose that 
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new drugs targeting the inflammasome components, such as caspase 1, may 
also show clinical benefit in the treatment of MetS and obesity. Also drugs that 
reduce activation of a subset of macrophages such as the M1 class may also 
prove useful in treatment of these conditions. 
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1.  INTRODUCTION 
 
 
A.  What is Metabolic Syndrome and why is it important? 
 
 Metabolic syndrome (MetS) is described as a set of risk factors that occur 
together and increase the chances for developing coronary artery disease, stroke 
and type 2 diabetes mellitus (T2DM). The definition for MetS from the American 
Heart Association/National Heart, Lung and Blood Institutes is:  “the presence of 
at least three of the following five criteria: waist circumference: men, greater than 
102 cm, and women, greater than 88 cm; triglyceride level of 1.695 mmol/L or 
greater; HDL-cholesterol level, less than 1.036 mmol/L; blood pressure of 130 
mmHg or greater systolic, or 85 mmHg diastolic, or taking antihypertensive 
medications; and fasting glucose level of 5.55 mmol/L or greater.”  Many of the 
risk factors for MetS are related to obesity.  The two most important risk factors 
are: “extra weight around the middle and upper parts of the body (central 
obesity)” and insulin resistance.  Insulin resistance is when the body does not 
use insulin effectively: blood sugar and fat levels rise even though insulin levels 
are also elevated.  In addition to central obesity and insulin resistance, other 
possible predisposing factors include aging, genetic predilections, hormonal 
triggers and living a sedentary lifestyle [1] [2].  
  MetS is becoming more common in the U.S. and around the world.  This 
increase parallels the doubling in prevalence of obesity worldwide since 1980 [3]. 
According to the American Heart Association (AHA), it is estimated that 47 million 
people have MetS in the U.S. alone [4].  Amazingly, the AHA predicts that 
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metabolic syndrome will soon beat out cigarette smoking as the primary risk 
factor for cardiovascular disease.  Living with the syndrome is dangerous and 
increases the risk for heart disease and T2DM, both chronic conditions.  In 
addition, MetS is associated with increased risk of developing polycystic ovarian 
syndrome, fatty liver, cholesterol gallstones, asthma, sleep disturbances and 
some forms of cancer [5].  
MetS is a growing problem that needs attention.  In 2002, a study of 
middle-aged Finnish men showed MetS was associated with a higher risk of 
death from heart disease and overall mortality [6]. A few years later, Malik and 
colleagues published a U.S. study in adults 30-74 years of age, which showed 
MetS was linked to an increase risk of CHD, CVH and total mortality [7]. 
(FIGURE 1) In addition, people with T2DM, MetS or pre-existing heart disease 
are at even higher odds of encountering health complications or death.  This 
large study, using data collected from over 6,000 subjects, revealed that even 1 
or 2 MetS risk factors are enough to significantly increase the possibility of heart-
related mortality.  Not only is metabolic syndrome life threatening, it also has 
devastating effects on life quality.  Relying on daily insulin injections or being 
unable to walk up stairs can certainly decrease ones’ enjoyment of life. 
MetS, characterized by IR and an “apple-shaped” physique, increases 
ones risk of developing T2DM and cardiovascular disease.  T2DM causes 
premature death and affects over 25 million Americans [8].  Sadly, as of 2011, 
11.8% of men and 10.8% of women over the age of 20 have diabetes.  
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Figure 1. The impact of MetS on CVD, CHD and overall mortality in U.S. 
adults 
Age- and Gender-adjusted mortality rates in U.S. adults in NHANES II follow up 
study.  (n = 6,255; mean follow-up is 13.3 years) MetS indicates Metabolic 
Syndrome, DM indicates Diabetes Mellitus, CVD indicates cardiovascular 
disease, CHD indicates coronary heart disease [7]. 
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T2DM is listed as the seventh leading cause of death in the U.S.  Among people 
with T2DM, cardiovascular disease accounts for 68% of these deaths.  The NIH 
reports, “the overall risk of death among people with diabetes is about double 
that of people without diabetes” [9].  It is estimated that there are roughly 6 
million undiagnosed people in the U.S. with T2DM.  It is the leading cause of 
kidney failure, lower extremity amputation and adult blindness.  
In addition to the toll IR takes on peoples’ lifespan, the healthcare costs 
associated with T2DM is around $174 billion per year. The cost of medical care 
for people with T2DM is estimated to be 2.3 times higher than those without the 
disease. Half of all direct medical costs (preventative, diagnostic and treatment 
services) in the U.S. were from inpatient care for complications attributed to 
T2DM.  Some of these complications include CHD, hypertension and depression.  
Also, T2DM causes high indirect costs, such as: increased absenteeism, reduced 
productivity at work and unemployment from disease-related disability [10]. 
From 1987 to 2000 per capita healthcare spending increased in large part (27%) 
due to the prevalence of obesity. It is important to note that, “approximately 2/3 of 
the costs from DM complications may have been averted with appropriate 
primary care for these conditions” [11].  All U.S. citizens bear the burden of these 
healthcare costs.  The poor health of some causes everyone to pay higher 
insurance premiums and taxes.  It is crucial to intervene as early as possible. 
Since there are not enough resources to pay for the proper care of people with 
MetS, physicians will be forced to concentrate on treating symptoms only. People 
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will not receive much-needed disease prevention assistance and risk factor 
control. 
The availability of an effective therapy to treat IR, perhaps during the pre-
diabetic phase, would help drive down these costs for our country.  More 
importantly, it would give physicians another option to treat high-risk individuals 
suffering from the complications of IR. There is no good reason to wait until 
people are symptomatic to treat them. Diabetes is becoming increasingly 
common in children.  Screening high-risk individuals and beginning early therapy 
will save money and suffering in the long run. The risk factors for MetS are 
relatively easy and inexpensive to screen for.  According to National Cholesterol 
Education Panel they are: abdominal obesity, elevated triglycerides, low HDL, 
increased blood pressure and impaired fasting glucose. In addition to these risk 
factors, given the data presented in this thesis, it would be helpful to measure 
pro-inflammatory cytokine levels as well.  
In order to make progress in the fight against MetS and IR, prevention and 
early treatment are critical.  The work presented here highlights some of the 
biomarkers that could be used to select the population most likely to respond to 
anti-inflammatory drugs before disease progression.   
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B.  What is Chronic Inflammatory Disease? 
 
Chronic Inflammation plays a critical role in the development and 
progression of disorders such as T2DM, cancer, Alzheimer’s disease and 
cardiovascular disease [12]. (FIGURE 2) In 2010, Kumar et. al. defined chronic 
inflammation as “a prolonged condition in which inflammation, tissue injury and 
attempts at repair coexist.”  White blood cell count is, “the most fundamental 
clinical measure of inflammation” [13].  The simple quantification of total 
leukocytes in circulation can predict risk of T2DM and heart disease in people 
without any current symptoms [14].  Specifically, it is the increase measured in 
the granulocyte sub-population that is informative, not the monocyte and 
lymphocyte counts [13].  Another way chronic inflammation shows up in clinical 
tests is by heightened levels of circulating pro-inflammatory cytokines.  For 
example, people with chronic heart failure have elevated tumor necrosis factor-
alpha (TNF-α) and interleukin-1beta (IL-1β) in the blood.  As heart failure 
progresses, the levels of these cytokines rise [12].  Also, a high level C-Reactive 
Protein (CRP) is now recognized as an independent risk factor for heart disease. 
T2DM is predicted by assessing circulating levels of IL-1β, IL-6 and CRP.  In 
each of these cases, inflammation seems to be intricately linked to disease 
progression.   
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Common causes and contributors to chronic inflammation in people with 
heart disease and diabetes include periodontal disease, flora in the gut, air 
pollutant exposure and genetic predisposition [13].  Obesity is also closely tied to 
sub-acute, chronic and indolent inflammation.  This kind of inflammation is 
different than the more acute form, that is associated with recent infection, tissue 
repair from injury and flares with autoimmune disease [13].  Continuous 
overeating causes a nutrient overload that is associated with chronic, low-grade 
inflammation in tissues, particularly the visceral fat depots [16].  Visceral fat is 
intraperitoneal fat, which is made up of greater and lesser omentum and 
meseneteric adipose tissue [17].   
 
C.  Inflammatory cytokines and chemokines and obesity 
 
The visceral fat makes many inflammatory cytokines and chemokines, such as 
TNF-α, interleukin-6 (IL-6), macrophage chemoattractant protein-1 (MCP-1) and 
leptin.  In the state of obesity, the production of these proteins appears to be 
often poorly regulated.  This is associated with a buildup of macrophage cells in 
the visceral adipose tissue.  It is unclear whether the macrophage cells arrive in 
the adipose tissue first (and then cause increased cytokine production in the 
area) or if increased cytokine production from the adipocytes cause the 
macrophages to gather.  Either way, in severely obese individuals, macrophages 
can account for an astounding 50% of visceral fat cellularity [18, 19].  
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Macrophage cells are divided into two subpopulations: M1 and M2 macrophages.  
They differ in that, “M1 macrophages secrete a characteristic signature of pro-
inflammatory cytokines, whereas M2 macrophages secrete anti-inflammatory 
cytokines” [20].  In the state of obesity, M1 macrophages are considered adipose 
tissue macrophages (ATMs) and M2 macrophages are the resident, anti-
inflammatory cells.  Obesity-associated chronic inflammation also involves 
organs other than adipose tissue, including the liver and endothelium.  Since 
obese individuals often also struggle with T2DM and/or atherosclerosis, it is 
possible that inflammatory dysregulation is a factor linking the disease states.  
 
At the molecular level, TNF-α, IL-1β, and IL-6 are strongly associated with 
the development of insulin resistance and MetS [13].  For example, TNF-α is 
found at high levels in obese animals and humans [21].  Also, insulin resistant 
obese individuals express higher levels of inflammatory cytokines compared to 
people who are insulin sensitive [22].  Nuclear factor kappa B (NF-κB) is the 
main intra-cellular regulator for the production of these cytokines, many of which 
signal through the JNK pathway.  The role of NF-κB and JNK pathways in linking 
obesity with inflammation and insulin resistance will be expanded upon in chapter 
2. 
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D.  Toll-like receptors and chronic inflammation 
 
Chronic metabolic inflammation may also result from increased triglyceride 
levels and may be due to increased Toll-like receptor (TLR) activity.  TLRs are an 
important part of the innate immune response.  They activate pro-inflammatory 
signaling in response to microbial pathogens. [23] In addition, “TLRs are present 
in adipocytes and can be directly activated by nutrients, particularly fatty acids” 
[24].  TLR4 binds to LPS (lipopolysaccaride) of gram-negative bacterial walls but 
altered levels or composition of fatty acids, including triglycerides, can also 
activate signaling by TLR4 in adipocytes and macrophages. (FIGURE 3) The 
activation of TLR4 induces inflammatory signaling in these cells, via NF-κB 
transcriptional activation [23]. 
 
E.  The Inflammasome’s role in Metabolic Syndrome and Chronic 
Inflammation 
 
There is growing interest in research on inflammasomes, since they may 
be highly relevant in the development of some forms of MetS [25, 26].  The 
inflammasome is a large complex found in the cytoplasm that can sense 
pathogen-associated and danger signals [27]. Inflammasome activity has been 
reported in macrophages, dendritic cells, epithelial cells and adipocytes [28, 29].  
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Figure 3. FFAs activate TLR4 signaling and induce a pro-inflammatory 
response 
A. FFAs activate TLR4 signaling in 293T cells (n = 6; *P < 0.01) [23]. Cells were 
transiently transfected withTLR4/MD2, with and without dominant negative 
MyD88-DN expression vector. MD2 is a co-receptor of TLR4.  MyD88 is an 
adaptor protein for TLR4 that is necessary for downstream signaling to activate 
NF-κB.   Also, cells received a NF-κB luciferase reporter construct. The 
transfected cells were treated with BSA, FFAs (200 micromolar oleate/palmitate 
mixture) or positive control, LPS (100 ng/ml) B.  FFAs can stimulate TNF-α 
expression in macrophages.  Palmitate causes dose-dependent expression of 
TNF-α in RAW264.7 cells, after 8 hour treatment at doses ranging from 1 to 1000 
ng/ml FFA.  LPS was used as a positive control. C. FFAs induce TNF-α mRNA 
expression in peritoneal macrophages from wild type mice, but not from TLR4 
knockout mice (n = 4, *P < 0.01).  Cells were treated with 200 micromolar FFA 
oleate/palmitate mixture for 8 hours.  RT-PCR was used to measure mRNA.  
Data expressed as mean +/- SEM. 
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Although the exact molecular mechanism of inflammasome activation is unclear 
in most cases, many labs are currently pursuing this area of research.  
Inflammasomes contain pattern recognition receptors (PRRs) to determine what 
factors are present in the cytoplasm.  Unlike Toll-like receptors (TLRs), that are 
cell surface membrane-bound receptors, these PRRs are intracellular and 
include the Rig-1-like receptors and Nod-like receptors (NLRs).  NLRs are large 
multimeric complexes that can recognize microbial signals and initiate immune 
responses to danger signals within the cell.  They can also be activated by 
metabolic dysfunction [30]. 
One well-studied NLR, nucleotide-binding domain, leucine-rich-containing 
family, pyrin domain-containing-3 (NLRP3, NALP3 or Cryopyrin), is part of an 
interesting inflammasome complex.  It is activated by danger signals, such as 
necrotic cell debris and noxious substances.  NLRP3 inflammasome is a complex 
made up of the NLRP3 regulatory subunit with an adaptor molecule called 
apoptosis-associated speck-like protein containing a CARD (ASC) and the 
effector subunit pro-caspase 1 [28]. (FIGURE 4) The activation of this 
inflammasome is a complex, multi-step process where cleavage of the caspase I 
precursor releases an active protease that starts a cascade that leading to the 
cleavage of other pre-proteins.  In the end, the activation of NLRP3 causes the 
production of IL-1β that is originally expressed as a latent precursor protein (“pro-
protein”).  Caspase-1 conversion is required to produce active and secreted 
forms.   
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Figure 4. NLRP3 inflammasome activation in obese adipose tissue adds to 
pathogenesis of disease 
Nlrp3 inflammasome activation in obese adipose tissue causes obesity-related 
pathogenesis [28].  Adipose of obese individuals contains adipocytes and 
macrophages.  Signals, such as cell debris and altered triglyceride levels or 
composition produce activation of caspase-1 in the Nlrp3 inflammasome.  This 
causes secretion of mature IL-1β, a pro-inflammatory cytokine.  Activation of this 
caspase cascade in adipocyte can cause downstream inflammation and 
differentiation.  Nlrp3 indicates nucleotide binding domain, leucine-rich-containing 
family, pyrin-domain containing-3, Asc indicates apoptosis- associated speck-like 
protein containing a CARD, IL-1β indicates interleukin-1 beta.   
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The cells containing active NLRP3 inflammasomes then secrete these pro-
inflammatory cytokines and undergo caspase-1 induced death, a process called 
pyroptosis [30].  Knockout mice lacking NLRP3, ASC or caspase-1 all develop 
lower levels of inflammation. 
 
The inflammasome in obesity and MetS  
Recent studies have examined the inflammasome’s pivotal role in obesity-
induced inflammation and insulin resistance [32].  Of importance is the role of 
caspase 1 activated IL-1β in the development of insulin resistance in obese 
individuals.  One set of studies examines steps leading to caspase-1 activation in 
obesity and focuses on the role of macrophages that infiltrate  
adipose tissue as adipocytes enlarge. (FIGURE 5) It is proposed that the 
macrophages become activated and produce IL-1β, promoting the development 
of insulin resistance. 
 Stientra’s group studied this hypothesis by testing a number of knockout 
animals lacking either the Nlrp3, ASC, or Caspase-1 gene involved in the 
inflammasome pathway [32, 33].  The three knockouts, as well as a wild type 
control, were fed a HFD for 16 weeks.  The investigators monitored food intake 
and body weight development week to week.  They also measured insulin levels 
as an assessment of insulin resistance and IL-1β production as an indicator of 
inflammation.  
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Figure 5. As obesity progresses, adipocytes enlarge and macrophages 
infiltrate the adipose tissue  
 A. db/db (diabetic) mice are an obesity model used to study diabetes and MetS 
[34].  They display increased body weight and increased adipose tissue mass. 
The animals have a point mutation in their leptin receptor gene causing leptin 
signaling to be disrupted.  B. Mac-2, otherwise known as Galectin-3, is a lectin 
expressed by activated macrophages.  This lectin mediates macrophage 
phagocytic and inflammatory responses [36]. The adipocytes shown here are 
hypertrophic and unhealthy.  As these cells swell and die, macrophages infiltrate 
the adipose tissue and promote an inflamed environment [37]. 
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They also measured leptin levels as these are positively correlated with an 
increase in obesity and resistin levels as this hormone impairs glucose tolerance 
and the effectiveness of insulin [34] [35]. Resistin, named for its’ association with 
resistance to insulin, is also an adipokine.  This newly discovered protein impairs 
glucose tolerance and insulin action [35].  The knockouts consumed a 
comparable amount of food as the wild type animals.  The results were striking.  
Although all three knockout animals consumed a comparable amount of food as 
the wild type animals, they failed to gain weight like the wild type animals when 
fed HFD.  Instead, their body weight gain was more like the low fat diet (LFD) 
trend line.  The IL-1β production and resistin levels were significantly lower in the  
knockout animals. The ASC and Caspase-1 knockouts had significantly less 
insulin and leptin in their plasma [32]. These results are consistent with a key role 
of caspase-1 activation in the development of obesity and MetS.      
 
2. HISTORICAL PERSPECTIVE ON USING ANTI-INFLAMMATORIES TO 
TREAT IR 
 
A.  When was this idea initially tested and by whom? 
 
Sodium salicylate’s history goes back to 1543 B.C., albeit in its unpurified 
form.  Willow tree bark and myrtle contain salicin [38].  It turns out that salicin, an 
alcoholic beta-glucoside, is closely related to the chemical structure of aspirin.  
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Aspirin, or acetylsalicylic acid, is commonly prescribed today to treat rheumatoid 
arthritis as well as other conditions associated with swelling.  An Egyptian 
medical text from 1543 B.C. reports the use of these plants as medicine.  In 400 
B.C. Hippocrates prescribed a powder made from the bark and leaves of the 
willow tree for fever and pain [39].  It wasn’t until the early 1800’s when salicylic 
acid was purified out of salicin extracts by Buchner and Leroux. (FIGURE 6)  An 
Italian chemist, Raffaele Piria, split salicin into sugar and salicylaldehyde.  Then, 
using hydrolysis and oxidation, he converted salicylaldehyde into salicylic acid.  
Since salicylic acid was extremely rough on the stomach, a gentler compound 
was developed a few years later.  Charles Gerhardt, a French chemist, buffered 
the drug using sodium and acetyl chloride.  He created acetylsalicylic acid, better 
known as aspirin.  By 1900 Gerhardt’s compound was picked up by a German 
chemist, Felix Hoffman, who convinced Bayer to market the drug, after he’d done 
some preliminary testing on his arthritic father.  The “wonder drug” was born.    
Aspirin was quickly adopted into routine use in many homes for pain and fever 
[40].  
Treating diabetics with anti-inflammatory drugs dates back to the 1800’s, 
before tolerability improvements were made by Dr. Gerhardt.  Professor Ebstein 
tested sodium salicylate as a potential therapy to treat diabetics.  The patients he 
enrolled were, most likely, a mixture of type I (insulin-dependent) and type II 
diabetics.  Although the study was not overwhelmingly successful, the small, 
landmark trial showed promise for treating a subset of diabetic patients [41].  
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In 1901, Williamson and Lond published a study titled, “On the treatment 
of glycosuria and diabetes mellitus with sodium salicylate” in The British Medical 
Journal. Williamson and Lond designed their study based on recommendations 
made by Professor W. Ebstein [42].  Although the drug was not very successful 
in its initial tests by Ebstein, Williamson set up a small trial in patients with severe 
cases of diabetes, as well as the milder form, to see if there was any potential 
therapeutic effects.  The article describes a patient who had a “milder form of 
diabetes or persistent glycosuria” that showed reduced sugar in her urine when 
she took sodium salicylate.  The “milder form of diabetes” was most likely T2DM. 
The article outlines the progress of one woman whose response to the  
drug was convincing.  The sugar in her urine decreased dramatically when given 
sodium salicylate (20grams, 4 times per day).  Then, her sugar level spiked back 
up when he took her back off the drug.  Then they re-started treatment, and saw 
restoration of the beneficial effects of sodium salicylate on the diabetic subject. 
The article notes, “in certain mild cases of diabetes or persistent glycosuria…  
(sodium salicylate) has a decided action in very markedly diminishing the sugar 
excretion.”  They went onto say, “the drug is not suitable in all cases of diabetes.  
It requires to be carefully watched, and fairly large doses are usually necessary 
to produce decided results.”  Dr. Williamson and Dr. Lond’s work concluded that 
although sodium salicylate does not work in all cases, it can help certain diabetic 
individuals with the moderate form of the disease [42].  
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B.  What did the first data show? 
 
Dr. Ebstein’s first study testing sodium salicylate in patients with diabetes 
showed some normalization of urine volume and sugar content.  Although the 
pathogenesis of diabetes was poorly understood during the 1800s, it was noted 
that daily salicylate therapy seemed to help people with a milder form of the 
disease, and not the more aggressive form.  At the time, the aggressive form was 
described with these hallmark symptoms: large amounts of sweet urine, wasting 
away of the body and a rapidly progressing disease.  Today this form of diabetes, 
type I diabetes, has been studied extensively.  Type I diabetes begins in 
childhood and is due to the body’s complete, or nearly complete, inability to 
produce insulin.  This lack of insulin production is caused by an autoimmune 
dysfunction that causes the body to destroy its’ own pancreatic beta cells.  These 
are the cells responsible for expressing and secreting insulin in the body to 
maintain glucose homeostasis.  On the other hand, Dr. Ebstein’s trial showed 
early signs of hope for people with the milder form of diabetes, today known as 
T2DM.  This form of the disease is associated with a slower progression, obesity 
and increased age.  T2DM patients suffer from insulin insensitivity, otherwise 
known as insulin resistance.  Although their bodies show high circulating levels of 
insulin, it is no longer effective at maintaining glucose homeostasis.  Daily 
salicylate doses of 10 grams per day caused tinnitus in Dr. Ebstein’s trial.  
However, he was able to lower the dose to 5-7.5 grams per day to reduce this 
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unwanted side effect while maintaining the normalization of urine volume and 
sugar content [41].  
 
C. What were potential shortcomings of early experiments? 
 
Dr. Ebstein’s trial showed a high level of failure probably due to the lack of 
knowledge at that time about the subtypes of diabetes and their different 
etiologies. This maiden study failed to target the correct patient population.  By 
mixing the two populations together in his study, type 1 and 2 diabetics, the 
actual benefits of the salicylate drug on the T2DM population was diluted out by 
the failures seen in NIDDM subjects.  Also, the doses given were extremely high, 
causing unwanted side effects like tinnitus [41].  
 
3.  TARGETING THE CORRECT POPULATION 
 
A. Who stands to benefit most from this treatment? When should 
intervention take place? 
 
 It is crucial to identify the appropriate population to test the efficacy of anti-
inflammatory drugs for MetS.  Due to the complexity of MetS and its’ numerous 
symptoms, some types of patients may be more suited to respond to an anti-
inflammatory intervention.  As an example, it could be dangerous to test these 
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drugs in patients who have lowered immune systems or are in the process of 
fighting an infection, since anti-inflammatory drugs often alter the immune 
response. In addition, as mentioned in the previous section, type 2 diabetics 
should be targeted, since their disease is fueled by an inflammatory component, 
not because they fail to produce insulin.   
 In 2010, Barbaroja et al, helped elucidate the different levels of 
inflammation within the obese population [22].  This work established the 
potential to use biomarkers to identify those patients who are obese and have 
MetS that will respond to anti-inflammatory drugs.  The study compared the level 
of mRNA and protein expression of inflammatory markers in visceral adipose 
tissue (VAT) between insulin resistant morbidly obese individuals (IR-MO), their 
non- insulin resistant counterparts  (NIR-MO), and a lean control group.  Each of 
the three groups contained 6 subjects that were age-matched and segregated by 
BMI: lean controls = 22.57 +/- 0.84 kg/m2, NIR-MO = 55 +/- 2.20 kg/m2, IR-MO= 
55.85 +/- 1.32 kg/m2.  BMI (body mass index) uses the ratio of weight and height 
squared in order to calculate underweight, healthy weight, overweight and obese 
ranges in adults [43].  The IR-MO group had the highest level of serum insulin, 
45.46 +/- 2.44 units/ml, compared with the NIR-MO (14.37 +/- 1.73 units/ml) and 
lean controls (7.19 +/- 0.41 units/ml).  The IR-MO group was the least healthy 
group based on HDL cholesterol level, 41.18 +/- 4.67 mg/dl, compared with NIR-
MO (49.00 +/- 5.91 mg/dl) and controls (58.75 +/- 5.1 mg/dl).  Also, the IR-MO 
group showed the highest level of triaclyglycerols, 159.18 +/- 33.50 mg/ml 
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compared with NIR-MO (115.62 +/- 13.98 mg/ml) and controls (78.83 +/- 9.82 
mg/ml).  The investigators found that IR-MO have significantly more TNF-α, IL-1β 
and IL-6 mRNA expressed in their visceral adipose tissue, as measured by real-
time PCR.  Also, on the protein level, they report roughly a two-fold increase in 
IL-1β and IL-6 levels in the visceral adipose tissue extracts.  (FIGURE 7)  Based 
on this data as well as histopathology showing the increased level of 
macrophage infiltration in IR-MO compared with NIR-MO VAT, the authors 
support the hypothesis that, “the effectors linking obesity and insulin resistance 
are inflammatory.”  So, IR-MO,  
might gain the most benefits for anti-inflammatory therapy.  These individuals 
display heightened levels of pro-inflammatory cytokine mRNA and protein, which 
are probably contributing to the severity of their MetS.  Also, this group is at the 
highest risk for possible cardiovascular events, due to heightened levels of 
triacylglycerol and lowered levels of HDL.   
In practice, measuring the mRNA and protein from VAT samples, as was 
performed in the Barbaroja study, may not be feasible.  The MO obese 
participants in this observational trial were undergoing gastric bypass surgery at 
the time of VAT tissue collection.  The control subjects were also in the hospital 
for invasive surgery.  In order to pre-screen individuals by these markers, it would 
be helpful to be able to test protein levels in the blood or in the subcutaneous fat 
depot in order to avoid invasive tissue sampling.  
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Figure 7. IR-MO express higher levels of pro-inflammatory cytokine mRNA 
and protein compared to NIR-MO and lean controls 
 Part 1 shows mRNA expression using real-time PCR for TNF-α (A), IL-1β (B) 
and IL-6 (C).  The total RNA was extracted from WAT tissue of lean controls, 
NIR-MO (non-insulin resistant morbidly obese) and IR-MO (insulin resistant 
morbidly obese).  Part 2 shows protein expression level of IL-1β (D) and IL-6 (E), 
from WAT samples using the Milliplex High Sensitivity Human Cytokine 
Immunoassay.  Results show + S.E.M. [22] 
 
 
 
 
 
 
 
 
 
 25 
The data from this study certainly provides a good rationale for treating IR-MO 
people with anti-inflammatories to attempt to control disease [22]. 
 
B.  What biomarkers can be used to screen at risk populations? 
 
An observational trial, called HaBPS or Hormones and Biomarkers 
Predicting Stroke, studied 1,889 post-menopausal women aged 50-79. HaBPS 
was an ancillary study of WHI-OS, the Women’s Health Initiative Observational 
Study [44]. The organizers of this study looked at weight phenotypes and how 
they related to inflammatory biomarkers in the blood.  Each woman was placed 
into one of the following 4 categories: normal weight women with 0-1 metabolic 
abnormalities and no diabetes (group I), normal weight women with 2 or more 
metabolic abnormalities and/or diabetes (group II), overweight/obese women with 
0-1 metabolic abnormalities and no diabetes (group III) and overweight/obese 
women with 2 or more metabolic abnormalities and/or diabetes (group IV).  
Normal weight was defined as a BMI between 18.5 and 24.9 kg/m2, while 
overweight/obese included the women with BMI’s over 25 kg/m2.  Four metabolic 
abnormalities were defined: blood pressure above 130/85 or taking a anti-
hypertensive, HDL over 1.3 mmol/L or taking a lipid lowering drug, triglycerides 
over 1.7 mmol/L and fasting glucose over 5.6 mmol/L CRP (C-reactive protein), 
IL-6, TNF-α and WBC counts were measured in all groups. The association of 
body size phenotypes with heightened inflammatory biomarkers was calculated 
using logistic regression “adjusted for age, race/ethnicity, smoking status, 
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income, physical activity, education, hormone therapy use, non-steroidal anti-
inflammatory drug use, baseline history of CVD and stroke case-control status.”  
The results of the HaBPS study showed that CRP, IL-6, TNF-α and WBC counts 
were highest in the overweight/obese group with 2 or more metabolic 
abnormalities and/or diabetes, group IV.  CRP is a well-known predictor of a 
cardiovascular event.  The normal weight group with 0 or 1 metabolic 
abnormalities had the lowest levels of all four markers. The results show an 
association between inflammatory markers and obesity/metabolic abnormalities. 
(FIGURE 8) The investigators of this study concluded that being  
both overweight/obese and/or having cardiometabolic abnormalities are 
associated with higher levels of inflammatory markers.  Overall, the odds ratio 
(OR had 95% confidence intervals (CI) of being in the top quartile of each 
inflammatory biomarker) of having more than 3 inflammatory markers in the top 
quartile is associated with body phenotype: if group I is set to an odds ratio of 1, 
then group II has OR of 2, group III has an OR of 2.3 and group IV has an OR of  
4.2 for being in the top quartile of inflammatory markers. Based on these results, 
the group that could most benefit from ant-inflammatory intervention is the 
overweight/obese group with 2 or more metabolic abnormalities and/or diabetes.  
The target inflammatory markers are highest in this group and they are at the 
most risk for serious complications, like heart attack or stroke.  
  This study showed that biomarkers for inflammation that are associated 
with cardio metabolic  risk, can easily be measured from blood samples.  
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By combining the biomarker data with standard anthropometric measurements 
(i.e. BMI and waist circumference) and blood pressure readings, the HaBPS 
study was able to organize a large number of individuals into risk groups.  Similar 
testing could be done to help find the correct population to treat with anti-
inflammatory medications.  Many of the biomarkers used in HaBPS are pro-
inflammatory cytokines that are known to be associated with insulin resistance 
and MetS [44].  
 
C.  Which measurable factors can predict Insulin Resistance? 
 
Since those who are insulin resistant also have higher levels of 
inflammatory markers, and therefore make better candidates for anti-
inflammatory treatment for their metabolic illness, it would be helpful to figure out 
which measurable factors can predict IR.  Early treatment and intervention 
generally favorably impacts the course of disease.  This kind of data may help 
identify the best candidates at an early stage, before metabolic abnormalities 
progress and full-fledged inflammation has set in.  In mid-2010 Manu, et al. 
published an article focusing on this question entitled, “Predictors of Insulin 
Resistance in the Obese with Metabolic Syndrome”.  
This publication pulled data from the National Health and Nutrition 
Examination Survey (NHANES) that ran from 1999 to 2004, and included 31,126 
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people aged 20-79 [45].  The investigators sifted through the massive dataset to 
find practical predictors of insulin resistance in people who were obese, but not 
diabetic. The participants took part in an interview, physical exam and some 
laboratory testing.  Some of the tests included:  insulin levels, serum glucose 
concentration, triglyceride levels, HDL-cholesterol levels, and CRP concentration. 
The Manu group limited their study to include men and non-pregnant women with 
a BMI over 18.5.  Also, they chose to include only participants who had fasted 8 
hours before blood draws and had completed all of the testing for insulin 
resistance and MetS parameters.  As stated above, they only tracked data of 
non-diabetic individuals, whose fasting glucose was lower than 125 mg/ml and 
who had never been told by a doctor that they had diabetes.  In the end, they 
studied a dataset consisting of 4,958 people.  They had a fairly even numerical 
distribution (1,500 roughly) between three body types: normal weight (BMI 18.5-
24.9), overweight (BMI 25-29.9) and obese (BMI over 30). 
Manu and colleagues divided the obese NHANES participants into two 
groups, ISO (insulin sensitive obese) and IRO (insulin resistant obese) [46]. 
Insulin resistance was measured using HOMA (homeostasis model assessment).  
A value can be calculated using the following formula: 
 Fasting Serum Insulin (uU/ml) X Fasting Plasma Glucose (mmol/l)  = IR 
                                                  22.5 
                                                                                                                [47] 
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Insulin resistance, in this case, is defined as “HOMA values greater than 5.52, 
the 90th percentile of the 4,598-participant cohort.”  The IRO group was made up 
of 373 people with HOMA values over 5.52.  HOMA levels ranged from 5.53 to 
52.22, with a mean value of 9.52 (S.D. = 5.73).  The ISO group also had 373 
members.  It was comprised of obese people with the lowest HOMA values, 
ranging from 0.14 to 2.45, with a mean value of 1.79 (S.D. = 0.44).   
 The results showed that 86.3% of IRO had MetS, while only 41.8% of ISO 
were considered MetS-positive.  In this case, the definition for MetS was taken 
from the American Heart Association/ National Heart, Lung and Blood Institutes 
guidelines described above.  The ISO, though similar to IRO in demographic 
characteristics like age, race and education, had some significant differences in 
terms of anthropometric and metabolic characteristics.  Both male and female 
ISO had lower BMI, smaller waist circumference, lower triglycerides, lower LDL 
and VLDL cholesterol, and higher HDL cholesterol, compared with their IRO 
counterparts.  Amazingly, 48% of IRO population was taking antihypertensive 
medication, while only 17% of ISO did.  By comparing the eating habits of IRO 
and ISO, the investigators discovered ISO consumed less cholesterol daily, 
though overall calorie intake and alcohol-related calories were not significantly 
different.  IRO individuals were more likely to smoke cigarettes than the ISO, 
24% and 18.9% respectively.  The conclusions reached from this study found 
that the most significant predictors of IR were: triglyceride level (P= 0.0021), BMI 
(P = 0.0096), HDL-cholesterol (P = 0.0098), age (P = 0.0242) and smoking (P = 
 31 
0.0366) [46].  Earlier studies have associated insulin resistance in humans with 
heightened triglyceride level in the muscle [48].  Smoking has previously been 
reported as an independent risk factor for diabetes in a large Korean study [49]. 
Based on this article, it may be best to screen for inflammatory markers in the 
individuals that are at the highest risk for becoming IR.  The expected benefit of 
screening only in this population is that the presence of inflammatory markers will 
better predict those individuals who might obtain better outcomes using anti-
inflammatory therapies.   
 
4.  DESCRIBE THE LINK BETWEEN INSULIN RESISTANCE AND 
INFLAMMATION 
 
A. Insulin signaling: the role of IRS-1 and IRS-2 in health and disease 
 
Insulin signaling occurs when the hormone, insulin, binds to the extracellular 
alpha subunit of the insulin receptor [50]. This binding event causes the 
intracellular beta subunit to become activated and it autophosphorylates. Then 
this phosphorylation event sets off tyrosine phosphorylation of intracellular 
substrates. Insulin receptor substrates, IRS-1 and IRS-2, become 
phosphorylated on multiple tyrosine residues in the process of insulin sensitivity 
maintenance.  The IRS proteins are phosphorylated by activated insulin 
receptors, IGF-1 and other cytokines.  Once IRS-1 and IRS-2 tyrosine 
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phosphorylation occurs, they can bind Src homology 2 domains in a variety of 
signaling proteins downstream. Some of the signaling proteins downstream of 
IRS include: PI 3-kinase, Grb-2 and SHP2.  PI 3-kinase activation induces 
recruitment of serine kinases to the plasma membrane.  One of the membrane-
associated serine kinases, protein kinase B/Akt, becomes activated by 
phosphorylation and it phosphorylates many downstream effectors.  The 
response created by this pathway includes, “stimulation of glucose transport, 
protein and glycogen synthesis, and the regulation of gene expression, which 
affects cellular proliferation and survival” [51, 52]. Since IRS-1 and IRS-2 are 
critical mediators of IR signaling, interfering with their function often has 
deleterious effects.  Components of the inflammatory response (SOCS proteins, 
adipokines, pro-inflammatory cytokines) can hinder IRS-1 and IRS-2 in a number 
of ways, including: decreasing normal tyrosine phosphorylation, impairing 
receptor expression and increasing proteosomal degradation [53].  Also, during 
chronic inflammation, IRS-1 can cause serine phosphorylation of the IR, thereby 
diminishing its’ responsiveness to insulin [54]. 
 
B.  Evidence that inflammation induces insulin resistance: TNF-α, IL-1β and 
IL-6 are key proteins 
 
Many proteins are involved in both inflammation and insulin resistance.  
Cytokines, such as TNF-α, IL-1β, and IL-6, which were initially discovered as 
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molecules that function in the inflammatory arena, are now known to be active 
participants in metabolic processes as well. These proteins are mostly expressed 
by macrophages that are activated by inflammation [31].  As discussed below, 
high levels of pro-inflammatory cytokines are associated with impaired insulin 
signaling in vitro. Looking at the effect of increased levels of TNF-α, IL-1β and IL-
6 on metabolic health is one way to examine the link between inflammation and 
IR.  These three pro-inflammatory cytokines will be discussed in detail. 
 
TNF-α 
 TNF-α is expressed by macrophages and adipocytes [55].  As its’ name 
suggests, tumor necrosis factor alpha can induce cell death in some tumor cell 
lines. Also, it is a potent pyrogen that causes fever [56].  TNF-α exerts its’ effects 
by binding two distinct cell surface receptors, TNFR1 (p55) and TNFR2 (p75).  
The receptors are present on all cell types (macrophages, monocytes, T cells, 
smooth muscle cells, adipocytes and fibroblasts), except for erythrocytes [57].  
Then, TNF-α activates transcription of NF-κB [58].  Although there is a lot of 
crosstalk between p55 and p75, TNFR1 is thought to be mainly responsible for 
carrying out TNF-α’s inhibitory effects on IR signaling pathway. Chronic 
inflammation and persistence of this pro-inflammatory cytokine can “induce 
changes in both lipid and glucose metabolism that are likely to have detrimental 
consequences for the host” [57].   
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A paper linking TNF-α protein activity to insulin resistance came out 
around the same time [59].  The group published data showing TNF-α was able 
to inhibit insulin-stimulated tyrosine phosphorylation of insulin receptor in Fao 
cells (insulin-sensitive hepatoma line). In this study, Fao cells were pre-treated 
for one hour with 5nM TNF-α, and then stimulated with 100 nM insulin for one 
minute.  The cell extracts were run on a western blot and probed with anti-
phosphotyrosine antibodies.  A band was seen around 185kD upon insulin 
treatment alone.  The bands’ intensity decreased by 65% in the sample that was 
pre-incubated with TNF-α.  An immunoprecipitation study revealed this band to 
be phosphorylated IRS-1. After longer exposure, a band around 95 kD, the 
insulin receptor beta subunit, became visible in the insulin-only sample.  Again, 
the amount of phosphorylated protein was reduced with TNF-α pretreatment.  In 
order to push the effects of TNF-α further, the group exposed Fao cells to 16 
hours of pro-inflammatory cytokine and then treated with insulin.  In this case, 
phosphorylation of the tyrosine on IRS-1 was completely wiped out.  TNF-α is 
capable of interfering with normal insulin action, and can lead to insulin 
resistance if the concentration is high enough.  This may be the case during 
chronic inflammation. 
In 1993, Hotamisligal and colleagues reported that TNF-α may also 
produce insulin resistance by affecting glucose transporters that are regulated 
through the insulin receptor [60]. The group compared TNF-α mRNA expression 
levels in lean and obese mice.  Southern blot analysis revealed the level of TNF-
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α mRNA was significantly higher in the epididymal fat tissue of the db/db animals 
compared with lean controls. (FIGURE 5) The db/db animal model is used to 
mimic diabetes in humans.  The animals have a point mutation in their leptin 
receptor gene, causing impaired leptin signaling [61].  The defect causes an 
inability to regulate energy stores appropriately.  In addition to the db/db model, 
they noted this same finding in three other obesity models, ob/ob mice, fa/fa rats 
and tub/tub mice. Ob/ob mice are leptin deficient, meaning they lack a protein 
involved in regulation of adipose mass.  The fa/fa rat expresses a dysfunctional 
leptin receptor, rendering the animals less sensitive to leptin.  Tub/tub mice 
display late onset obesity, due to a mutation causing loss of function of the tubby 
gene.  In this study, they used a cell separation technique to look at expression 
levels in the adipocyte fraction and stromal-vascular fraction separately.  In both 
cell populations, they saw increased TNF-α mRNA levels from the obese animal 
samples.  In a follow up study, they measured the amount of TNF-α protein in 
adipose tissue and in the circulation of 24 control and 24 obese animals.  Obese 
adipose tissue had double the level of TNF-α protein compared with lean 
animals.  In plasma, ELISA results showed 25% of lean animals had sufficient 
TNF-α to be detected (mean 61.53 +/- 11.9 pg/ml) while db/db animals had 
detectable levels in 58.3% of the samples (mean 85.6 +/- 10 pg/ml). In cell 
culture experiments, the investigators showed mature murine 3T3-F442A 
adipocytes express little to no GLUT4 RNA after 10 days of TNF-α treatment.  
They also measured RNA levels of GLUT4 from epididymal fat pads of lean and 
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obese mice and found GLUT4 levels go down with increased adiposity.  GLUT4 
(HUGO name SLC2A4) is a member of the solute carrier family 2 and acts as an 
“insulin-regulated facilitative transporter” [62].  It is expressed in muscle and fat.  
The GLUT4 gene is down-regulated during insulin resistance and obesity.  
In addition to rodents, TNF-α is also overproduced in the adipose and 
muscle tissues of obese humans [21]. It is clear that overproduction of TNF-α in 
adipose tissue is an important feature of obesity with the potential to increase 
insulin resistance.  
 
IL-1β 
 IL-1β also helps tie together the story of inflammation and insulin 
resistance on the protein level [63].  IL-1β is synthesized as an inactive IL-1β 
precursor species.  Its production is initiated by TLR agonists, such as LPS.  In 
order to form fully active IL-1β, co-localization with procaspase-1 must occur.  
Once the two proteins have come together, the IL-1β inflammasome converts 
inactive procaspase-1 to functional caspase-1.  Caspase-1 then processes the 
IL-1β precursor into mature IL-1β.  Monocytes, macrophages, and other cell 
types secrete IL-1β protein.  IL-1β stimulation of IL-1 receptors causes many 
physiological manifestations, including fever production, rashes and IL-6 
production.  
 In a similar manner to TNF-α, IL-1β can alter insulin signaling in vitro [63, 
64]. In one study, cells were treated for 6 days (3T3-L1s) or 8 days (3T3-F442A) 
 37 
with 0, 10 or 20 ng/ml IL-1β.  On the last day, they were then stimulated with 100 
nmol/l insulin and then the protein was extracted from the cells.  Equal amounts 
of protein were loaded per lane in a quantitative western blot for phosphorylated 
forms of IR-β, IRS-1, Akt/PKB, and ERK1/2.  In each case, the investigators 
probed for total, unphosphorylated protein as a control.  In both differentiating 
3T3-F442A and differentiated 3T3-L1 cells, IL-1β treatment inhibited acute insulin 
activation [31].  Tyrosine phosphorylation on insulin receptor beta subunit, as well 
as IRS-1, decreased in these experiments in a dose-dependent manner.  IL-1β 
treatment also reduced by 40-75% the insulin-induced activation of Akt/PKB.   
Akt/PKB is “a key enzyme of the insulin signaling pathway mainly involved in 
short term metabolic responses” [31].   IL-1β also reduced the insulin-induced 
activation of ERK1/2 in these two cell lines, as measured by western blot.  
ERK1/2 is a mitogen-activated protein kinase.  It helps mediate part of the 
insulin-stimulated transcription. (FIGURE 9) The study was repeated with less IL-
1β (0.1 and 1ng/ml).  In this case they report a decrease of 25 and 35% 
respectively for insulin-induced phosphorylation of Akt/PKB.  In addition, shorter 
incubation time (24 hours) with a lower concentration of IL-1β (1ng/ml) was also 
capable of driving down phosphorylation of Akt/PKB and ERK1/2 significantly.  
These studies show how a classic pro-inflammatory cytokine, IL-1β, can potently 
induce insulin resistance in vitro [31].  
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Figure 9. IL-1β Inhibits insulin-induced glucose transport and lipogenesis 
in 3T3-F442A and 3T3-L1 murine adipocytes 
Differentiated 3T3-F442A (from days 0-8) and fully differentiated 3T3-L1cells 
(from days 8-14) received IL-1β at the concentrations indicated [31].  On day 8 
(3T3-F442A) or day 14 (3T3-L1) the cells were treated with 100 nm/l insulin for 
10 minutes and then glucose transport was evaluated by tracking the amount of 
2-deoxy-D-[14C]-glucose (A, B).  Glucose transport results were expressed as 
pmol of 2-deoxy-glucose per 10 cells per 5 minutes+/- SEM.  IL-1β treatment 
significantly altered the cells’ ability to transport glucose after insulin exposure.  
After insulin stimulation, proteins were extracted from cells and run on western 
blots probing for SLC2A4 (GLUT4) (C,D). The blots were analyzed by 
densitometry and displayed in arbitrary units in bar graphs.  Expression levels of 
GLUT4 protein was not significantly effected by IL-1β treatment.  Glucose 
incorporation into lipids was evaluated (E,F).  Lipogenesis results were 
expressed as pmol glucose incorporated into lipids per 10^6 cells per 24 hours 
+/- SEM.  IL-1β inhibited lipogenesis in both cell lines.  All experiments were run 
three times, in triplicate.  Open bars are insulin-stimulated samples, closed bars 
are basal values.  *p < 0.05, **p < 0.01, ***p < 0.001.  Control basal value vs. IL-
1β-treated basal value: ‡p < 0.05, ‡‡‡p < 0.001 
 
 
Further in vitro testing showed that IL-1β significantly inhibited insulin-
stimulated glucose transport in 3T3-L1 and 3T3-F442A, by 84% and 86% 
respectively [31].  Normally, within ten minutes of insulin stimulation, GLUT4 
translocates to the cell surface from the cytoplasm of muscle cells and  
adipocytes to facilitate transport glucose across the membrane. The investigators 
hypothesized the reason for the reduced transport of glucose was due to 
changes in this pathway.  Since they found only a small change in GLUT4 mRNA 
and no change in protein expression level (with or without IL-1β treatment) they 
attributed the reduction in glucose transport to the location of the transporter 
inside the cell.  Murine adipocytes were treated for 8 days (3T3-F442A) or 14 
days (3T3-L1) with 0,10, and 20ng/ml IL-1β, as described above.  On the final 
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day, 2-deoxy-D-[14C]-glucose transport was evaluated.  IL-1β reduced insulin-
induced lipogenesis, (14C-glucose incorporation into lipids) by over 90% in both 
cell lines. (FIGURE 9) 
 Finally, the article demonstrates how IL-1β suppresses adiponectin 
production in two murine cell lines, as well as in human primary adipocytes [31].  
Adiponectin concentration in the circulation is used as an index for insulin 
sensitivity [65].  It is made exclusively by adipocytes (adipokine) and is secreted 
into the plasma.  Adiponectin enhances glucose utilization and fatty acid 
combustion.  It can also antagonize TNF-α by down-regulating its’ expression in 
macrophages.  It is considered anti-diabetic, anti-atherogenic and anti-
inflammatory in nature.  The investigators report a significant reduction in 
adiponectin protein and mRNA expression following treatment with 10 and 
20ng/ml IL-1β in differentiating 3T3-F442A, fully differentiated 3T3-L1 and 
differentiated human primary adipocytes [31].  
 
IL-6 
 Interleukin-6 (IL-6), briefly mentioned above, is another cytokine that 
strengthens the link between insulin resistance and inflammation.  “IL-6 is the 
main cytokine involved in an acute-phase response” [66]. It can act as both a 
pro- and anti-inflammatory cytokine.  IL-6, along with ciliary neurotrophic factor 
(CNTF), IL-11, leukemia inhibitory factor, oncostatin M, and cardiotrophin 1 are 
all members of the gp130 cytokine family.  IL-6 binds to the IL-6 receptor, which 
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induces signal though a gp130 homodimer [67]. IL-6 is released from immune 
cells during inflammation, but can also be expressed and secreted from non-
immune cells, such as adipocytes.  Human adipocytes actually account for 15-
35% of IL-6 secreted into the circulation [68].  BMI correlates with serum IL-6 
concentration [69]. On the flip side, weight loss and improvement in insulin 
sensitivity is associated with falling levels of IL-6.  IL-6 level was one of the first 
cytokines used to predict the pathogenesis of insulin resistance [67].  
 Rotter, et al, studied the action of IL-6 in vitro using differentiated 3T3-L1 
murine adipocytes [70]. Acute treatment (30 minutes) with IL-6 did not increase 
phosphorylation of serine 307 on IRS-1.  Nor did IL-6 reduce insulin-stimulated 
tyrosine phosphorylation of IRS-1. 
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Figure 10. IL-6 treatment reduces IRS1 and GLUT4 expression and impairs 
glucose transport in 3T3-L1 cells 
A. IL-6’s effect on IRS1 RNA expression [70]. (top) 3T3-L1 cells were incubated 
without (bas) or with (IL-6) 20 ng/ml IL-6 for 24 hours.  RNA extraction was 
performed and the samples were run on Northern blot.  18S RNA is used as a 
loading control. (bottom) quantification of data in Northern blots.  Results are 
mean +/- S.E. of three experiments compared with basal control (run once). (*, p 
= 0.04) B.  IL-6’s effect on GLUT4 mRNA expression. 3T3-L1 cells were 
incubated without (bas) or with (IL-6) 20 ng/ml IL-6 for 24 hours. mRNA was 
extracted and RT-PCR was performed, using 18S as a reference.  Results are 
mean +/- S.E. of four experiments (*, p < 0.05) C.  Glucose transport in 3T3-L1 
cell with IL-6 treatment. Cells were incubated without (bas) or with 20 ng/ml IL-6 
for 24 hours.  Then some (+ins) were treated with 100nM insulin for 30 minutes.  
Then glucose transport was measured.  Results shown are mean +/- S.E. of 
three experiments (*, p < 0.05)  
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However, IL-6 (20 ng/ml) did cause a clear reduction in IRS-1 RNA level in 3T3-
L1s after 24 hours of treatment. (FIGURE 10)  This expression level correlated 
with a 50% decrease in IRS-1 protein, as measured using an anti-IRS-1 western 
blot. Pre-incubation with IL-6 for 24 hours inhibited insulin stimulated tyrosine 
phosphorylation of IRS, compared with control cells stimulated with insulin alone.  
The amount of inhibition seen with IL-6 pretreatment is similar to the extent to 
which IRS-1 protein expression is reduced by IL-6.  In contrast, IL-6 did not 
inhibit insulin-stimulated insulin receptor tyrosine phosphorylation.  Altogether, 
the authors conclude that 24-hour exposure to IL-6 can hinder insulin signaling 
through a decrease in IRS-1 RNA and protein expression.  In order to explore 
this finding further, the authors went onto show the effect of long term (24 hour) 
IL-6 treatment on GLUT4 mRNA level.  The results showed that 20 ng/ml IL-6 
significantly (P < 0.05) reduced GLUT4 expression, as measured by real time 
PCR (18S reference).  GLUT4, a crucial protein for insulin action, is directly 
affected by prolonged IL-6 exposure.  In addition, IL-6 treatment, followed by 100 
nM insulin exposure for 30 minutes, caused glucose uptake rate to slow in the 
cells compared with controls.  (P < 0.05) (FIGURE 10)  In this case, IL-6 creates 
an environment where insulin stimulated glucose uptake is less efficient and thus 
contributes to insulin resistance.   
In one human observational study, investigators found plasma IL-6 
concentration correlated with insulin resistance [71]. Twenty-one healthy  
 44 
patients, without history of chronic disease or long-term medication use, 
underwent a 4-hour euglycemic hyperinsulinemic clamp with insulin infusion at 
40 mU/m2/min.  Also, they measured whole body glucose uptake, glucose 
disposal, fat percentage and C-peptide.  The study concluded that IL-6 
concentration inversely correlated with insulin sensitivity in healthy subjects.  In 
addition, IL-6 concentration did correlate with C-peptide level, fat percentage and 
blood pressure.     
 A human genetic study investigated insulin sensitivity in a group of 
individuals with an IL-6 gene polymorphism, characterized by lower plasma IL-6 
levels [66]. People who were “homozygous for C allele at position -174 of the IL-6 
gene… showed significantly lower integrated area under the curve of serum 
glucose concentrations after an oral glucose tolerance test, lower blood 
glycosylated hemoglobin, lower fasting insulin levels… and an increased insulin 
sensitivity index than carriers of the G allele.”  This study was conducted with 11 
C/C subjects and 21 G/C or G/G subjects, similarly matched in age, BMI and sex.   
Although it is a relatively small study, the significance in glucose tolerance (P = 
0.001) and HbA1c % (P = 0.002) show clear differences in insulin sensitivity  
regarding levels of IL-6 gene expression.  In this case the data shows that 
decreased levels of IL-6 correlates with increased insulin sensitivity. 
 In summary, TNF-α, IL-1β and IL-6 contribute to insulin resistance by 
interfering with insulin receptor signaling and glucose uptake. All three cytokines 
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are associated with poor GLUT4 transporter expression.  TNF-α and IL-1β inhibit 
insulin-stimulated tyrosine phosphorylation of the insulin receptor, in a dose- 
dependent fashion.  IL-1β suppresses adiponectin levels and causes reduced 
activation of Akt/PKB and ERK1/2.  IL-6 treatment can lower IRS-1 mRNA and 
protein levels in vitro.  Taken together, this data suggests inflammatory cytokines 
can negatively impact insulin sensitivity.      
 
C. Which animal models support the link in vivo between inflammation and 
insulin resistance? 
 
TNF-R and TNF-α knockouts 
 To test the role of TNF-α in insulin resistance, mouse models with 
targeted null mutation in the genes encoding TNF-α or the two receptors that 
mediate TNF-α signaling (p55 and p75) have been generated. Lack of TNF-α 
resulted in “significantly improved insulin sensitivity.”  Knockout animals fed a 
standard diet also had lower fasting blood glucose levels compared to controls.  
Strikingly, after 12 weeks on HFD, “the fasting insulin levels in the obese TNF-α 
+/+ group were increased roughly fourfold compared with those of the obese 
TNF-α -/- mice”. (P < 0.05)  (FIGURE 11) Overall body weights were similar 
between knockouts and controls on both standard and high fat diets over the 16-
week study. The effect of TNF signaling was also tested in ob/ob mice.  These 
mice are insulin-resistant.  
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Figure 11. Mice lacking TNF-α (cytokine or receptor) have lowered fasting 
plasma glucose and insulin and increased GLUT4 expression in muscle 
tissue 
A. (top) Fasting glucose levels in TNF-α -/- and wild type mice on chow and HFD 
at 4, 8 and 12 weeks. B. (top) Fasting insulin levels in TNF-α -/- and wild type 
mice on chow and HFD at 4, 8 and 12 weeks.  A. (bottom) Fasting glucose levels 
in ob/ob p55 -/- p75 -/- , ob/ob controls, p55 -/-p75 -/-  and wild type mice at 4, 8 
and 12 weeks of age. B. (bottom) Fasting insulin levels in ob/ob p55 -/- p75 -/- , 
ob/ob controls, p 55 -/-p75 -/-  and wild type mice at 4, 8 and 12 weeks of age. *P 
<0.05.  From Uysal, 1997  [72] 
  
 
 
Mutations were introduced in the TNF-α receptors, p55 and p75 to produce a 
(ob/ob p55-/- p75-/-) strain to assess the role of TNF-α signaling in insulin-
resistance.  These mice had lowered fasting glucose concentration compared 
with standard ob/ob animals.  Also, fasting plasma insulin levels were 
significantly lower in ob/ob p55-/-p75-/- compared to ob/ob wild-type controls at 
week 12 of the study [72].  
All of the TNF-α knockout models show a substantial increase in blood 
glucose clearance rate following glucose injection (glucose tolerance test, GTT). 
In addition, insulin tolerance testing (ITT) revealed that TNF-α deficient animals 
on HFD cleared blood glucose more efficiently than wild-type controls following 
an insulin injection.  TNF-α KO animals appeared partially protected from the 
insulin insensitivity caused by high fat, high calorie feeding.   
Other studies have also investigated the link between increased TNF-α 
levels and insulin resistance in vivo. In addition to inhibitory effects on IRS-1 
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signaling, the insulin sensitive glucose transporter GLUT4 is also altered. Obese 
TNF-α -/- mice had increased GLUT4 protein expression in their muscle tissue.  
It is possible that up-regulation of this glucose transporter is contributing to the 
improved insulin sensitivity in the knockout animals [55, 73]. 
 
IL-1R1 knockouts 
 Mice lacking Interleukin-1 Receptor I (IL-1RI-/-), the receptor for IL-1β, 
have improved glucose homeostasis on a high fat diet [74].  The knockout 
animals are protected from adipose inflammation often associated with high fat 
feeding.  In this study, the investigators tracked the effects of IL-1R1 signaling 
loss on both inflammation and glucose metabolism.  Both lean and obese IL-1R1 
-/- animals had improved GTT and ITT. (FIGURE 12) In order to explain the 
reason for the improved glucose tolerance in receptor knockouts, the group 
measured recruitment of macrophages into the adipose tissue.  HFD caused a  
major increase in recruitment of macrophages to adipose, though there was no 
difference seen between the knockout and wild-type strains.  In order to look 
more closely at the cells being recruited under HFD conditions, the group 
focused on macrophages double positive for F4/80 and CD11b surface markers.  
F4/80 is a macrophage cell surface protein commonly used as a cell-type 
marker. [75] CD11b is the alpha chain of the Mac1 integrin. It’s expressed on 
neutrophils, monocytes and macrophages. [76] The group sorted F480+/CD11b+ 
macrophages from adipose tissue from knockouts and controls and seeded them 
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in cell culture plates (both M1 and M2 macrophages). After 24-hours in culture, 
the media was run in ELISAs for TNF-α and IL-6, that are produced by pro-
inflammatory M1 macrophages.  The ATMs from IL-1R1 knockout obese mice 
secreted significantly reduced IL-6 and TNF-α cytokines compared with controls.  
(FIGURE 12)  In addition to these findings, the article reports the IL-1R1 -/- group 
had an “attenuated inflammatory profile” in adipose tissue of animals on a HFD. 
Adipose tissue was extracted and cultured for 24-hours in serum-containing 
media. 
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Figure 12. IL-1R1 knockouts have improved glucose and insulin tolerance 
on HFD compared to WT; ATMs from IL-1R1 -/-s secrete fewer pro-
inflammatory cytokines, IL-6 and TNF-α 
A. GTT in WT and IL-1R1 -/- mice at baseline and on HFD. 1.5 g/kg glucose 
given after a 6 hour fast. *** P < 0.001 with respect to IL-1R1 -/- obese, ### P < 
0.001 with respect to IL-1R1 lean. B. ITT in WT and IL-1R1 -/- mice at baseline 
and on HFD.  6-hour fasted animals received 0.75 units/kg of insulin, *P < 0.05 
and ***P < 0.001 with respect to IL-1R1 -/- obese. C and D (lower). area under 
the curve for GTT and ITT data from A and B.  Data is expressed in arbitrary 
units (AU), *P < 0.05, ***P < 0.001 with respect to corresponding WT, ##P < 
0.01, ###P < 0.001 with respect to corresponding lean animals. D and E. (right)  
Immunogenic phenotype of isolated ATMs from WT and IL-1R1 -/- animals,  
SVCs (stromovascular cells) were separated from adipose tissue by collagenase 
digestion and then F4/80 and CD11b positive macrophages were collected and 
deposited into tissue culture dishes, 200,000 cells per well in a 24-well plate.  
Cells were incubated in complete media for 24 hours before cultures were 
harvested.  ELISAs were run to measure IL-6 and TNF-α secretion from the WT 
and IL-1R1 -/1 animals ATMs. [74] 
 
They used ELISA to measure pro-inflammatory cytokine levels (IL-6, TNF-α, IL-
1β) in the cell supernatant, compared with wild-type animals.  Cytokine secretion, 
specifically IL-6 and TNF-α, was significantly lower in animals lacking IL-1R1.  
Parallel data showed mRNA levels also went down for IL-6, TNF-α and SOCS3 
in the knockout samples. Suppressor of cytokine signaling 3 (SOCS3) is a 
cytokine-inducible negative regulator of JAK2 kinase signaling. In this study, the 
investigators prove that lack of IL-1R1 signaling in obese animals partially 
protects them from adipose inflammation as well as insulin resistance.   
 
Toll-like Receptors and Obesity 
The TLR family of receptors sense pathogen-associated molecular 
patterns and activate an innate immune response in mammals involving 
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inflammasomes as described in Chapter 1.There are four classes of TLR. Of 
these, lipopolysaccaride (LPS) and nonbacterial agonists (i.e. fatty acids) can 
specifically activate TLR4. Once turned on, TLR4 signaling induces up-regulation 
of intracellular inflammatory pathways that result in the release of cytokines 
related to the induction of insulin resistance.  These pathways involve c-Jun 
NH2-terminal kinase (JNK) and IκB kinase complex (IKKβ)/ inhibitor of nuclear 
factor-κB (IκBα)/ nuclear factor-κB (NF-κB). 
 
TLR4 Knockouts 
The hypothesis that TLR4 receptors play a role in obesity and MetS is 
supported by study of Toll-like receptor 4 (TLR4) knockout animals.  A key 
observation by Tsukumo is that mice without functional TLR4 (C3H/HeJ strain) 
had lower adiposity and displayed increased insulin sensitivity on HFD [77, 78].  
C3H/HeJ mice were also less prone to diet-induced obesity and insulin 
resistance than the control C3H/HeN strain [78]. The animals also had increased 
oxygen consumption and insulin-signaling ability in adipose tissue and muscle 
compared with controls (C3H/HeN) on HFD.  Control mice on HFD had higher 
JNK and NF-κB activity compared with TLR4 deficient animals.  The detailed 
results show that C3H/HeJ mice on HFD for 8 weeks had lower body weight 
compared to C3H/HeN.  (FIGURE 13)  After 8 months on HFD, the body weight 
difference was more pronounced, averaging 15% lower in TLR4 knockouts on 
HFD.  At the end of the animal experiment, HFD-fed C3H/HeJ mice had 40% 
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less fat in their epididymal fat pads compared to controls.  In addition, the TLR4-
deficient animals on HFD had lower blood leptin levels (36%), smaller 
adipocytes, and fewer macrophages in their epididymal WAT.  Specifically, 
C3H/HeJ mice on HFD had around 10-fold lowered CLS (crown-like structures) 
formation compared to controls. (FIGURE 13) CLS can be seen under a light 
microscope using immunolabeled antibodies that specifically recognize 
macrophages.   
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Figure 13. TLR4 KOs gain less weight on HFD, have fewer CLSs in their 
WAT and have improved insulin and glucose tolerance compared to control 
mice 
A.  Body weight measurements of C3H/HeJ (TLR4 knockouts) and C3H/HeN 
(control strain) over 8 weeks on HFD and chow diet. * P < 0.05 (control mice on 
HFD vs. all other groups) B.  Body weight differences (same as A) after 8 months 
on HFD and chow diet. **P < 0.01 (control mice on HFD vs. all other groups) F-I 
(in box).  Epididymal fat pad histology from F (control chow), G (control HFD), H 
(HeJ chow), I (HeJ HFD). Scale bar represents 50 um for all images.  5 micron 
thick sections were stained with hematoxylin and eosin. H. GTT after 8 weeks on 
chow or HFD for control and TLR4-knockout animals.  P < 0.01(HFD controls vs. 
all other groups) I.  Insulin response curve taken during the GTT in  part H.  #P < 
0.05 (HFD controls vs. all other groups) 6-8 mice in all groups, data presented as 
means +/- standard error. [78] 
 
The structure looks like macrophages have completely surrounded the adipocyte.  
The adipocyte inside is considered either dead or dying.  The amount of CLS is 
used to indicate the number of dead adipocytes and the degree of macrophage 
infiltration into obese adipose tissue.  The appearance of CLS is associated with 
high BMI and adipocyte hypertrophy.  Interestingly, the infiltration of 
macrophages into the adipose is “temporally associated with the appearance of 
insulin resistance” [37].  Tsukumo et al.’s results support an essential role for 
TLR4 in producing insulin resistance [78]. After 8 weeks on a HFD, insulin 
tolerance tests showed glucose clearance rate was slower (in response to 
insulin) for C3H/HeN control mice compared with TLR4 C3H/HeJ knockouts.  No 
difference was observed on a normal chow diet.  Intra-peritoneal glucose 
tolerance test (IGTT) measured blood glucose levels following a glucose infusion.  
HFD-fed control mice had higher blood glucose concentrations at all time points 
measured compared with C3H/HeJs.  ITT revealed C3H/HeJ mice on HFD did 
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not become insulin resistant.  Their insulin levels remained in line with animals on 
chow diet, while HFD-fed controls had increased insulin concentrations [78]. 
 
 The in vivo studies presented here, along with many others, have proven 
that inflammatory cytokines play critical roles in metabolic function.  High levels  
of pro-inflammatory cytokines can hinder insulin sensitivity, while knocking out 
their expression can help maintain glucose homeostasis on HFD. 
 
D.  Which cell signaling pathways are common to inflammation and insulin 
resistance? 
 
Inflammation-activated intracellular pathways can lead to downstream insulin 
resistance.  Inflammation and insulin resistance are both associated with  
activation of the NFκB and JNK pathways [79].    
 
NF-κB  
NF-κB is an inducible transcription factor that mediates rapid and transient 
changes in gene expression with effects on cell survival, proliferation and 
differentiation. Although important for healthy skeletal muscle and the epithelial 
function, NF-κB’s most critical roles are in immune system development and 
function.  When NF-κB activation is persistent, inflammatory disease often 
becomes a problem.  In chronic inflammatory conditions, “pro-inflammatory 
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cytokines drive activation of NF-κB and the activation of NF-κB drives pro-
inflammatory cytokine production” [80]. Under normal circumstances NF-κB 
dimers are bound to inhibitory IkB-α and are only present in the cytoplasm, 
where they are inactive.  IκB-α, also called NF-κ-B inhibitor alpha or I-κ-B-α, 
inhibits NF-κB by trapping it in the cytoplasm by covering its nuclear localization 
signal.  This resting state is overcome when stimuli activates the IkK kinase 
complex (made up of IKKα, IKKβ and IKKδ).  This leads to IκB-alpha protein 
phosphorylation, ubiquitination and degradation.  Once the NF-κB dimer is freed 
from IκB-α, it translocates to the nucleus, binds DNA and turns on transcription of 
target genes.  (FIGURE 14)  Some of the genes transcribed include pro-
inflammatory cytokines, such as IL-1β, TNF-α, and resistin.  At this point the 
positive feedback loop has come full circle; the cytokines that activated NF-κB  
have stimulated production of more of the same cytokines.   
 
Jun NH2-terminal kinases    
JNKs (Jun NH2-terminal kinase) are activated by inflammatory cytokines, like 
TNF-α, and free fatty acids (FFAs) [81]. Activated JNK associates with IRS-1 and 
phosphorylates it, specifically at serine 307.  JNK-mediated serine 307 
phosphorylation inhibits insulin action by interfering with insulin-stimulated 
tyrosine phosphorylation [82]. In fact, literature reports increased serine 
phosphorylation of IRS-1 in type 2 diabetics and insulin resistant individuals [83]. 
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Studies have shown that mutation of serine 307 to alanine eliminates TNF-α 
stimulated phosphorylation of IRS-1 by JNK. 
 
E. The Molecular Consequences of Obesity 
  
            The mechanism whereby obesity turns on signaling of JNK and NF-κB is 
still being elucidated [84, 85]. The proposed mechanisms involve the cytokine 
and TLR pathways discussed above and also non-receptor mediated pathways 
involving cellular stress. 
 
 
Figure 14. Cellular mechanisms that activate inflammatory signaling and 
can cause downstream IR 
 [79] 
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TNF-α, IL-1β, and other pro-inflammatory cytokines, activate the two pathways 
through receptor-mediated mechanisms.  This kind of classic ligand/receptor 
activation is common and well understood.  Another receptor pathway involving 
TLRs that can activate JNK and NF-κB is not as well characterized, particularly 
the ligands that activate it.  What is known is that in the state of obesity, TLR4 
binds to, and is activated by, saturated fatty acids [86]. RAGE ligands include 
AGEs (advanced glycation end products) and microbial products, different from 
those that bind TLRs [87]. Over time, the state of hyperglycemia can cause 
increased levels of AGEs throughout the body.  AGEs are, “nonenzymatic 
adducts formed between glucose and targeted proteins, particularly those with 
slow rates of turnover.”  The non-receptor mechanisms that can activate JNK and 
NF-κB are intracellular stresses, like ROS (reactive oxygen species) and ER 
stress.  Increased BMI correlates with higher systemic markers of oxidative 
stress.  Treating hyperglycemic mice with antioxidants, specifically N-acetyl 
cysteine, can improve insulin resistance [88]. Also, as lipid accumulates inside fat 
and liver cells, the unfolded protein response is activated.  This causes increased 
ER stress, which is known to activate JNK and NF-κB. Finally, ceramides, lipids 
made up of sphingosine and a fatty acid, form during times of cell stress and are 
capable of activating JNK and NF-κB inflammatory pathways.  With all of these 
contributors to JNK and NF-κB coming from both inside and outside of the cell, it 
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is hard to tell which factor (s) drive signaling the most dramatically.  JNK and NF-
κB activation causes the production of many pro-inflammatory cytokines.  These 
newly expressed proteins are able of find a surface receptor to activate, thereby 
feeding into the cycle from which they came [79]. (FIGURE 14) 
 
Conclusion:  Based on many years of data, it is clear that pro-inflammatory 
cytokines and stimuli can cause signal activation of JNK and NF-κB.  Activation 
of these two cascades can cause insulin resistance through IR/IRS-1 inhibition 
and increased expression of pro-inflammatory cytokines, such as TNF-α, IL-1β, 
IL-6 and resistin.  Therefore, proteins involved in the inflammatory response can 
contribute to insulin resistance. 
 
F.  Therapeutic Approaches 
 
The potential for anti-inflammatory drugs is that they could grant millions 
of people, in the U.S. alone, the ability to enjoy longer, healthier lives Early 
intervention with safer drugs, like Salsalate, is a huge step forward. Many anti-
inflammatory drugs have been used for years and are well-tolerated. Therefore 
treating IR in a preventative manner is reasonable since the risks are low.  This 
approach could save significant amounts money, if successful. Also, the suffering 
associated with untreated, chronic-inflammatory-IR, such as blindness and 
kidney failure, could be alleviated.  There is a huge need for a drug of this kind.  
 61 
MetS is rampant in the U.S. and many other places on the globe.  It is time to be 
pro-active in its treatment.  It is time to think beyond the currently available 
medications, since they are only marginally useful. It is time to use the exciting 
data coming from research labs and capitalize on the newly discovered 
inflammatory component of IR. Using anti-inflammatory drugs to treat IR could be 
an effective, safe treatment for high-risk groups.  Further research is needed to 
explore the full potential of this approach. 
Currently, there is a major need for therapeutics to treat insulin resistance 
and obesity.  Sadly, the number of patients who could benefit from therapy 
continues to grow.  This new body of data linking insulin resistance and 
inflammation could offer novel ideas on ways to treat disease.  Perhaps the 
inflammatory component of IR can be capitalized upon by using it to find new 
therapeutic targets. 
Possibilities include: 
 1.  Inhibition of cytokines 
 2.  Inhibition of JNK and NF-κB pathways 
 3.  Inhibition of inflammasome components 
 4.  Inhibiting activation of TLR4 
 5.  Inhibition of pro-inflammatory M1 macrophage infiltration of the adipose  
                tissue 
6. Existing non-steroidal anti-inflammatory drug 
These are discussed in turn. 
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1.  Inhibition of cytokines:  Since the pro-inflammatory cytokines implicated in 
IR are secreted proteins (i.e. TNF-α, IL-1β, IL-6), extracellular inhibition can be 
useful to dampen their effects.  This could be achieved by injecting soluble TNF-
α receptor or IL-1 receptor, which would potentially sop up the cytokines in 
circulation and reduce signaling.  Alternatively, an anti-cytokine antibody could 
achieve the same result with more specificity.  Also, administration of a natural 
inhibitor of cytokines, such as IL-1RA in the case of IL-1β, is another approach 
that may help combat IR.  IL-1RA binds competitively to the IL-1R in the same 
place as IL-1β, however it does not turn on receptor signaling.     
2. Inhibition of JNK and NF-κB pathways:  The signaling pathways JNK and 
NF-κB offer more options for intervention locations.  Although intracellular drug 
delivery can be challenging, there is plenty of tantalizing data that supports this 
approach.  For example, TNF-α phosphorylates serine 307 (through the JNK 
pathway) on IRS-1, which inhibits insulin signaling.  Blocking this phosphorylation 
event and/or decreasing JNK activation could prove to be a useful therapeutic 
option.  Also, down-regulation of NF-κB could create a less-inflamed 
environment.  NF-κB activity causes the expression and secretion of pro-
inflammatory cytokines.  This pathway can be disrupted at multiple points.  NF-
κB activity could potentially be interrupted using any of the following methods: 
IkK kinase inhibition, IκB activation, blocking degradation of IκB, decreasing ROS 
or ER stress, and inhibiting NF-κB directly [89]. 
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3.  Inhibition of inflammasome components: As mentioned in section 1, the 
inflammasome is a new discovery linking inflammatory and metabolic function in 
a single pathway, one that offers many novel targeting sites for therapeutic 
disruption [25, 26, 28, 32]. Blocking either the NLRP3 subunit, ASC or the 
caspase-1 enzyme could potentially decrease the inflammasome’s activity.  The 
net result would be a decrease in the amount of IL-1β secreted from the cell.  
Since increased concentrations of these cytokines are associated with IR in 
obese individuals, this approach warrants attention. 
4. Inhibiting activation of TLR4: Animal studies discussed in section 4B above 
indicate that targeting of TLR4 receptors may be beneficial in reducing 
inflammatory processes within adipose tissue. Indeed it is hypothesized that one 
class of anti-diabetic drug, the thiazolidinediones, indirectly inhibit the TLR4 
pathway. 
5. Inhibition of pro-inflammatory M1 macrophage infiltration of the adipose 
tissue: This approach is aimed at reducing the burden of activated macrophages 
within adipose tissue.  
6. Existing non-steroidal anti-inflammatory drug:  Finally, the low-grade, 
chronic inflammation state observed in IR can be blocked more generically on a 
systemic level, using an NSAID (non-steroidal anti-inflammatory drug) [90]. 
NSAID medications, including salicylates (i.e. aspirin), propionic acid derivatives 
(i.e. ibuprofen), and acetic acid derivatives (i.e. indomethacin) have been used 
for years with low risk of side effects [39]. NSAIDs exert their effect by non-
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selectively inhibiting COX1 and COX2 enzymes (cyclooxygenases).  Without 
NSAIDs onboard, COX enzymes catalyze the formation of prostaglandins and 
thromboxane (via arachadonic acid).  Prostaglandins are messenger molecules 
that are involved in inflammation.  Aspirin’s mechanism of action has been well-
studied. It inhibits COX via the covalent addition of an acetyl group to a serine 
residue in the active site of COX, thereby irreversibly inactivating it. Steroids 
have similar anti-inflammatory capacity as NSAIDs and could be used as an 
alternative way to treat IR.  
 
5.  ANTI-INFLAMMATORY DRUGS TESTED IN VIVO 
 
A.  Which drugs are we talking about? 
 
Two classes of drugs are currently in use: small molecules and protein-based 
biologics 
1.  Small molecules:  There are many kinds of anti-inflammatory drugs currently 
available.  They range from over-the-counter, small molecule NSAIDs to 
prescribed, anti-TNF-α antibody proteins. The array of systemic and highly 
targeted drugs used to treat inflammation is always growing due to an expanding 
demand.  The sites of action of these drugs can be specific (i.e. pancreatic beta 
cells), more generalized (adipose, muscle, liver tissue) and in some cases, 
unclear.   
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 Salicylates are one of the most routinely used NSAIDs. Aspirin is an 
acetylated form of salicylate, while sodium salicylate, salsalate and trilisate are 
non-acetylated forms.  Salicylates have been used by millions of people to treat 
joint pain for years [91]. The non-acetylated salicylates do not affect COX1 and 
COX2.  At high doses, non-acetylated salicylates (as well as aspirin) inhibit 
IKKβ/NF-κB pathway.  High dose aspirin therapy is limited by its’ risk for 
gastrointestinal bleeding [92].  A safer alternative, salsalate (a dimer of salicylic 
acid), can inhibit NF-κB with similar potency as aspirin without the risk of 
bleeding [93].  Salsalate is a small molecule that is taken orally.  It has a short 
half-life and requires more than once-a-day dosing [91]. 
 TZDs (thiazolidinediones, a.k.a. “glitazones”) are currently used to treat 
T2DM.  These drugs are PPAR-γ ligands, capable of promoting insulin sensitivity 
in vivo.  PPAR-γ (Peroxisome proliferator-activated receptor- gamma) is a 
nuclear receptor that plays key roles in adipocyte development and glucose 
homeostasis.  Although the exact function of glitazones is still under research, 
early data suggests they act by positively and negatively regulating PPAR-γ gene 
expression in adipose, liver and skeletal muscle tissues.  TZDs also have potent 
anti-inflammatory action that adds to their insulin-sensitizing effect [20].  They 
can act through the PPAR-γ receptor to negatively influence the production of 
inflammatory mediators associated with insulin resistance.  For example, in fat 
cells “TZDs inhibit the expression and/or biological effects of IL-6, TNF-α, 
plasminogen activator inhibitor-1 (PAI-1), monocyte chemoattractant protein-1 
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(MCP-1), and angiotensinogen.”  In addition, TZDs activate PPAR-γ in 
macrophage cells, which inhibits the inflammatory response pathways from TLR 
and IFN-γ [94].  IFN-γ (a.k.a. Type II interferon or immune interferon) is a soluble 
cytokine that has pro-inflammatory activity and is involved in host defense 
mechanisms.  IFN-γ increases production of other cytokines and potently 
activates macrophages. [95] Unfortunately, TZDs treatment is associated with 
many adverse effects, including weight gain, increase in bone fractures, and 
heightened risk for heart disease [20]. 
2. Biologics: These protein therapies include solubilized receptors that act as 
traps as well as antibody-based products that alter receptor signaling or block 
cytokine action 
 Direct TNF-α blockade can be achieved using neutralizing antibodies to 
TNF-α or soluble TNF-receptor “traps”.  Etanercept (trade name Enbrel, Pfizer) is 
currently used to treat rheumatoid arthritis, plaque psoriasis, and a number of 
other autoimmune disorders. It inhibits TNF-α by acting as soluble, circulating 
TNF-α trap or “decoy receptor”.  The molecular design used to express 
Etanercept is the soluble portion of TNFR2 fused to human Immunoglobulin G1 
(IgG1).  It is a dimer of human p75 TNF-α receptor 2, linked to human IgG1 Fc 
fragments [96]. The DNA construct is transfected into cells that express and 
secrete the protein. Infliximab (trade name Remicade, Janssen Biotech, Inc.) is 
also used to treat autoimmune diseases by blocking TNF-α.  It is a monoclonal 
antibody that binds TNF-α and interferes with receptor binding.  This antibody 
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was originally produced in a mouse, and was developed into a mouse-human 
chimeric antibody in order to reduce immune response in humans. In addition, 
Remicade has been shown to kill off T lymphocytes that are producing TNF-α 
[97]. Infliximab (and other anti-TNF-α antibodies) differs from Etanercept since it 
can neutralize extracellular, transmembrane and receptor-bound TNF-α, while 
Etanercept cannot interfere with receptor-bound TNF-α action.  Adalimimab 
(Humira, Abbott) is another anti-TNF-α antibody, similar to Remicade.  Humira is 
unique, however, since it is a fully human monoclonal antibody, produced using 
phage display.  All TNF-α inhibitors suppress the immune system.  Therefore, the 
drugs have many side effects including: new or worsening infections, blood 
disorders, slight increased risk of lymphoma and liver disease, anaphylaxis, 
injection site pain/ swelling, headache and lupus [98-100]. 
 Inhibiting IL-1β signaling may improve insulin sensitivity, given its’ function 
in both the metabolic and inflammatory arenas.  The cytokine’s activity can be 
down-regulated by targeting the IL-1R1 and/or IL-1β itself [101]. Also, IL-1RA 
(receptor antagonist) is a natural inhibitor of IL-1β, and therefore recombinant 
protein administration could prove therapeutic.  Anakinra (Kineret, Amgen) is a 
recombinant version of IL-1RA that blocks natural IL-1β activity.  It competes with 
IL-1β for binding to IL-1R.  It is widely prescribed to treat the inflammation of 
rheumatoid arthritis, since these patients tend to have low concentrations of 
natural IL-1RA in circulation.   Side effects of Anakinra include:  nausea, 
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diarrhea, allergic reaction, infections, inflammation at injection site and abdominal 
pain [102].  
Three IL-1β-specific antibodies are currently in trials or approved for other 
indications.  They are designated: XOMA 052 (gevokizumab, Xoma), ACZ885 
(canakinumab, Ilaris, Novartis) and LY2189102 [91, 103].  Gevokizumab is in 
phase II and III clinical trials to treat inflammatory diseases, including non-
infectious uveitis (NIU).  NIU is characterized by intraocular inflammation and 
problems with visual clarity.  According to Xoma’s website, gevokizumab, “is a 
potent (humanized) monoclonal antibody with the potential to treat patients with a 
wide variety of inflammatory diseases… binds strongly to IL-1β.”  Canakinumab 
is a human monoclonal antibody to IL-1β, already being prescribed in the U.S..  It 
was approved to treat cryopyrin-associated periodic syndromes (CAPS).  CAPS 
includes a number of auto-inflammatory diseases, such as Muckle-Wells 
syndrome and familial cold auto-inflammatory syndrome.  No serious side effects 
have been reported. Novartis is currently testing canakinumab in RA, Diabetes 
and ocular disease [104].  Lily’s drug, LY2189102, is being tested in a Phase II 
trial for Type II Diabetes.  The results for this IL-1β-specific antibody have not 
been published [105]. IL-1 antagonists, as well as TNF-α blockers, are large 
proteins that require injection.  Their effect lasts anywhere from weeks to months 
[91]. 
 
 
 69 
B. What evidence is available from animal studies for the effectiveness of 
anti-inflammatory drugs? 
 
1.  Small molecules:  In 2001, Shoelson and Yuan reported aspirin and sodium 
salicylate were able to improve glucose tolerance and insulin signaling in obese 
and insulin resistant animals [106].  The study was conducted in rats and mice 
predisposed to insulin insensitivity.  They tested the effect of aspirin at 120 
mg/kg/day of for 3-4 weeks via continuous subcutaneous infusion.  In Zucker 
fatty rats, aspirin treatment improved both fasting blood glucose levels and 
glucose tolerance.  Also, the animals had lower insulin concentrations on the 
salicylate therapy compared to vehicle-treated controls. (FIGURE 15) Less 
insulin is often linked with higher insulin sensitivity. Also, high dose aspirin 
treatment significantly lowered free fatty acid (FFA) levels after only one week.  
FFA concentration dropped from 3.1 +/- 0.3 mM to 1.1 +/- 0.2 mM after three 
weeks on aspirin.  Blood triglyceride levels in fatty rats fell from 494 +/- 68 mg/dl 
to 90 +/- 58 mg/dl after three weeks of aspirin therapy.  Hepatotoxicity was not 
observed as a side effect.  Similar results were reported in ob/ob mice.  They 
chose to test aspirin’s activity in ob/ob mice (in addition to fa/fa rats) since they 
“are a more relevant model for type 2 diabetes, as the animals are diabetic in 
addition to being obese and severely insulin resistant.”  Both Zucker fatty rats 
and ob/ob mice are hyperphagic due to inactive leptin signaling.     
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 The Shoelson group reported that insulin responsiveness increased in 
liver and muscle tissue in obese animals on aspirin treatment.  They wanted to  
follow up on their animal data to find possible reasons (on a protein level) why 
aspirin therapy could improve insulin sensitivity.  Liver and muscle tissue from 
aspirin-treated and control Zucker rats were analyzed for insulin receptor (IR) 
activity.  After looking at level of tyrosine phosphorylation on the IR as well as 
phosphorylation of AKT (a downstream protein in the insulin-signaling cascade), 
they discovered aspirin treatment caused a “barely detectable” insulin signal to 
become highly detectable.  This data was depicted in western blots.  (FIGURE 
15) Both IR tyrosine phosphorylation and AKT phosphorylation went up when 
these rats received the anti-inflammatory drug, salicylate.  Tyrosine 
phosphorylation of IR indicates healthy, active insulin responsiveness.  
2.  Biologics:  In 1993, a group from Boston demonstrated that neutralization of 
TNF-α using TNFR improved glucose uptake in response to insulin in vivo [60].  
This study was carried out using obese fa/fa rats, which are insulin-resistant.  In 
order to block TNF-α, the scientists administered a recombinant, soluble TNF-α 
receptor fused to immunoglobulin G.  It was given IV for three days (200 ug per 
animal).  This dosing regimen resulted in blood concentrations in the range of 
47.69 +/- 4.79 ng/ml of receptor. Insulin sensitivity was measured using 
hyperinsulinemic-euglycemic clamps.  The clamp measures the amount of 
glucose needed to compensate for rising insulin level. If a high level of glucose is 
needed (based on blood test), the animal is sensitive to insulin. 
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Figure 15. Aspirin/Sodium salicylate treatment improves glucose tolerance 
and lowers insulin concentrations in fa/fa rats and ob/ob mice via a 
mechanism involving increased insulin receptor responsiveness 
 Zucker fatty rats and ob/ob (Lep ob/ob) mice treated with aspirin, 120mg/kg/day 
for 3-4 weeks using continuous infusion Alzet pumps.  Rats were 12 weeks old, 
mice were 8 weeks old.  All animals were given free access to food and water.  
Data are mean +/- SEM values.  Diamond and dashed lines represent controls 
with pump implants receiving vehicle only.  Circles and solid lines represent 
animals that receiving 3-4 weeks of aspirin treatment.  A.(left) Blood glucose 
concentration during GTT on Zucker fa/fa rat.  Rats were given 2g/kg glucose by 
oral gavage after an overnight fast. *P < 0.05, **P < 0.01 for vehicle vs. aspirin 
treatment, Student’s t test.  B. (left)  Serum insulin concentrations during GTT in 
panel A. P = 0.0004 for vehicle vs. aspirin treatment, integrated area under the 
curve. 6 animals/group. E.  ITT in Zucker fa/fa rats using 2U/kg insulin injected 
intraperitoneally following overnight fast.  P = 0.0001, for vehicle vs. aspirin 
treatment, integrated area under curve G. Blood glucose concentrations from 
GTT in ob/ob mice, P = 0.004  for integrated areas under curves.10 mice per 
group,   Inset in G. Fasting serum insulin concentration in ng/ml, *P <0.01.  A 
(right) and B (right) Zucker fa/fa rats protein expression from controls, aspirin-
treated and sodium salicylate-treated animals after 3-4 weeks of treatment.  
Animals were given insulin or saline intravenously 7 minutes before being killed.  
Liver and muscle tissue was removed, frozen in liquid nitrogen, homogenized 
and run on western blots. A shows data from liver samples and B from muscle 
samples. For IP:IR panels, before blotting the homogenates were 
immunoprecipitated using anti-Insulin Receptor antibody and then probed wth 
anti-phospho tyrosine and anti-IR (as a loading control).  The IB panels were 
homogenates run directly on gels to separate and probed with anti-phospo-AKT 
and anti-AKT (as a loading control). 
 
 
 
If only a small amount of glucose is required, the animal is considered insulin 
resistant.  After 5 and 25 mU (per kg body mass/minute) constant insulin 
infusion, the control and TNFR-IgG-treated rats had similar plasma insulin 
concentrations.   Also, the concentration of plasma glucose and rate of glucose 
infusion was stable in both groups of animals. (FIGURE 16)  In order to maintain 
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euglycemia under high insulin conditions, the “TNFR-treated animals required 
two to three times more glucose… indicating a greater response to insulin.”  In 
order to find a possible reason for this improvement in homeostasis, they 
followed the two major components of insulin regulation.  The first, stimulation of 
peripheral glucose uptake, is measured by Rd (glucose utilization rate). The 
second is suppression of hepatic glucose output, HGO.   Technically, this 
analysis is performed using tracer studies in the glucose clamps.  TNFR-treated 
animals had 2-3 fold higher insulin-stimulated peripheral Rd compared to 
controls.  On the other hand, HGO remained unaffected by TNFR treatment.  
Therefore, the insulin sensitivity caused by blocking TNF-α is most likely related 
to increased peripheral glucose uptake.   
Blocking IL-1β with a monoclonal antibody was reported to improve 
glycemic control in obese, hyperglycemic mice [101]. They tested male, C57BL/6 
wild type mice, either being fed high fat (HF) diet (60% fat, 20% carbohydrate 
and 20% protein) or low fat (LF) diet (70% carbohydrate, 20% protein, and 10% 
fat). Then HF and LF groups were divided again, into those receiving IL-1β 
antibody (Ab) or control antibody (C-Ab). 
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The IL-1β antibody in this study had an affinity of 300 pM.  It was given intra-
peritoneally once per week (10 ug per gram of body weight). Obese animals had 
significantly higher levels of HbA1c compared with lean (4.9% +/- 0.17 and 4.2% 
+/- 0.08, respectively).  The 13-week study showed anti-IL-1β-treated obese 
animals had, “reduced glycated haemoglobin (*P = 0.049, 0.45%), reduced 
serum levels of pro-insulin (*P = 0.015), reduced levels of insulin and smaller islet 
size (*P = 1.65E-13) relative to the control antibody-treated group.”  (FIGURE 17)  
Ob/ob diabetic mice have pancreatic islet cells that are 3.6 times greater in 
volume (hypertrophy) than ob/+ control mice (total cell number is similar between 
the two groups) [107]. 
Blocking IL-1β reduced serum amyloid A (SAA) significantly (P = 0.004).  
This indicates that the antibody is having an effect on inflammation-induced 
acute phase response. The antibody treatment did not affect the development of 
obesity in these animals. However, it seems blocking IL-1β in mice on a high fat 
diet can improve glycemic control and beta cell function. 
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C. What have clinical trials in humans shown? 
 
1. Small Molecules:  One early clinical trial testing an anti-inflammatory drug 
for a metabolic condition was conducted at Yale University School of 
Medicine [108].  Dr. Shulman and colleagues studied the effects of high-
dose aspirin in Type II diabetics. 
2.  
 
 
 
Figure 17. Anti-IL1β antibody treatment in mice on low fat and high fat diets 
causes reduction in HbA1c, proinsulin and insulin levels 
Table 1. Obese mice (on HF diet for 13 weeks) had higher body weight, 
increased concentrations of insulin, leptin, HbA1c and IL1Ra compared to lean 
animals on LF diet.  These animals were 19 weeks old (7-12 animals per group).  
A.  Glycated hemoglobin was significantly reduced in obese animals treated with 
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IL-1β antibody compared with control antibody  (*P = 0.049) B. Proinsulin 
concentration was significantly reduced in obese animals treated with IL-1β 
antibody compared with control antibody (*P = 0.015) C.  Insulin concentration 
was reduced in animals treated with IL-1β compared with control antibody. For A, 
B, and C: measurements were taken after 13 weeks of antibody treatment (Ab= 
anti-IL1b, C-Ab = control antibody). E.  IL-1β antibody treatment significantly 
decreased islet size in obese mice. Data are presented as means +/- SEM. 
 
 
Based on animal data published over the ten previous years, they wanted to see 
if IKKβ inhibition by aspirin would be able to help correct the inflammation and 
insulin resistance in this population.  Nine type II diabetics (BMIs 37 +/- 3 kg/m2) 
were treated with 7 grams of aspirin per day for two weeks.  During the study, 
participants took 200 ug of misoprostol four times a day to try to prevent high 
dose aspirin side effects, like gastric ulcers.  Blood salicylate concentrations were 
monitored throughout the study and doses were adjusted to keep levels between 
25-35 mg/dl.   
After two weeks on aspirin, they measured fasting blood glucose, which 
had significantly decreased from 164 to 125 mg/dl (P < 0.0001) from baseline.  
Also, serum cholesterol and triglycerides decreased to healthier levels (P values 
of 0.01 and 0.009, respectively). CRP levels decreased to 0.59 from a baseline 
0.71) after aspirin regimen (P = 0.02). Unfortunately, HDL levels (“good 
cholesterol”, cardio-protective) went down significantly (P = 0.01) with aspirin 
therapy. Also, the participant’s weights held steady at around 109 kg (+/- 7 kg).   
Aspirin’s side effects included tinnitus and mild hearing loss. Tinnitus is when a 
 78 
person thinks they are hearing a sound in their ears or head, but there actually 
isn’t any external sound source present.  This study, although small and relatively 
short, did not show much promise for treating obesity in this manner.  On the 
other hand, aspirin’s ability to lower blood glucose makes it a hopeful candidate 
for treating diabetes.  
In 2008, Dr. Shoelson’s group conducted three clinical trials testing 
salsalate  (Disalsid) in Type 2 Diabetics [92].  The group chose to test 
nonacetylated salicylate in this human study since they “do not modify COX 
enzymes, inhibit platelets, or prolong bleeding time and are therefore not 
associated with increased bleeding risk.”  Disalsid is also an affordable, dimeric 
prodrug that is insoluble inside the stomach’s acidic pH environment.  The first 
study treated patients with 4.5 grams Disalsid per day, in three 1.5 gram doses 
for two weeks.  The second study gave participants 3 grams per day, in two 1.5 
gram increments for two weeks.  These two trials were both open label, meaning 
both the people giving and taking the drug are aware of what is being given.  The 
first two studies’ subjects also received 200 ug misoprostol orally, four times per 
day throughout the 14-day period and 3 days leading up to it. The third trial was 
double-masked (blinded) and lasted 4 weeks at the maximum tolerable dose, 3 
grams per day.   No misoprostol was given in the third trial.   
The authors reported a significant decrease in resting blood glucose of 19 
% from trial one (4.5 g/day group) and a 9% drop from trial two (3g/day group).  
Also, they noted improved fasting insulin levels from both trials due to slower 
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clearance of insulin.  Interestingly, the group reported a 40% decrease in fasting 
triglycerides in trial 1 and 11% decrease in trial 2.  Total cholesterol was lowered 
by 12% in the 4.5gram/day salsalate study, however, no change was seen at the 
3 grams/day dose.  The salsalate therapy was able to improve glucose disposal 
by 43% as measured by exogenous glucose infusion rates (GIR) using 
euglycemic-hyperinsulinemic clamps at 4.5grams /day dose.  Standard 
inflammation markers, such as CRP and soluble CD40L, decreased significantly 
at the higher dose.  They saw no change in body weight at either dose.  
Salsalate therapy had marked side effects at 4.5 grams/day.  Out of the 7 people 
treated with the more aggressive does, six complained of tinnitus and/or 
headache. The 3 grams /day trial participants did not report tinnitus or 
headaches.  These studies showed hopeful markers for glucose disposal and 
slower insulin clearance.   
2.  Biologics:  In 2006, a clinical trial was conducted to see the effect of 
Etanercept on people with the metabolic syndrome (BMI around 36) [96]. The 
clinical study tested 50 mgs subcutaneous dosing of Etanercept once a week for 
4 weeks with a placebo control.  At the end of the trial they measured CRP, IL-6 
levels, lipid levels and body composition.  Before dosing, they divided the two 
groups of 28 participants as equally as possible, based on baseline 
characteristics such as BMI, race, glucose sensitivity, blood pressure and drugs 
they were currently taking.  All inflammatory marker endpoints, such as CRP, IL-
6 and fibrinogen, decreased with Etanercept treatment.  Also, adiponectin 
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concentration increased with Etanercept onboard.  There was no change in BMI, 
total fat or lean mass, total cholesterol, triglycerides or sensitivity to insulin. The 
drug was generally well tolerated and created very few adverse events.  Only 
one out of the 28 people on Etanercept stopped treatment due to low white blood 
cell count.  The trial was able to demonstrate decreased inflammation in these 
obese individuals with Etanercept.    
In 2007, a group from Novo Nordisk published the results of their clinical 
trial of an interleukin-1 receptor antagonist, anakinra (Kineret, Amgen), in type 2 
diabetics [102].  IL-1β is capable of disturbing the pancreatic beta cells 
responsible for making insulin inside the pancreas.  In a diabetic person, the 
consistently high concentration of glucose in the body feeds the production of IL-
1β by the pancreatic beta cells.  Then, the IL-1β acts upon the same cells that 
produced it, by disturbing cell function or even causing apoptosis. Type 2 
diabetics have lower levels of this beta cell-protective antagonist and an over-
expression of the IL-1β pro-inflammatory cytokine.  By boosting levels of the 
antagonist with a recombinant form, the study designers hoped to rebalance the 
biology within the pancreatic islets.  
The primary endpoint marker of this 70-person (average BMI = 31) trial 
was reduction in glycated hemoglobin. Glycated hemoglobin (HbA1c) levels are 
between 4-6% in healthy individuals.  Diabetics generally have HbA1c levels 
above 6.5%, and physicians try to maintain the level lower than 7% with drug 
therapy.  HbA1c level gives the clinician an idea of blood glucose control over the 
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past 2-8 weeks. The study also tracked data on inflammatory markers and BMI.  
Thirty-four patients took 100 mgs/day of anakinra subcutaneously.  The placebo 
group had 36 patients.  The 13-week study was conducted in a double-blind 
manner.   By the end of week 13, the anakinra group HbA1c level fell 0.33 
percentage points (from 8.69 +/- 0.17 to 8.37 +/- 0.21) and the placebo level went 
up 0.13 percentage point (from 8.23 +/- 0.28 to 8.37 +/- 0.46).  Therefore, the 
between-group difference was 0.46 percentage point (P = 0.03).  Also, both 
inflammatory markers CRP and IL-6 levels decreased significantly after 13 weeks 
of anakinra.  At the end of 13 weeks, the patients on anakinra did not have any 
“significant changes in BMI”.  This drug was well tolerated and no study 
participants dropped out due to adverse events.  The only heavily reported AE 
was “transient injection-site reactions” in 17 of 34 people taking the drug.  This 
reaction spontaneously cleared up within 6 weeks [102].  
 
6.  FUTURE STUDIES TO TEST IF ANTI-INFLAMMATORY MEDICINES WILL 
BE BENEFICIAL TO TREAT INSULIN RESISTANCE 
 
A.  What kinds of animal studies would help determine the best places to 
block inflammation?  What is the most effective way to suppress IR-linked 
inflammatory activity?  
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 Two kinds of animal studies have been presented here that help explore 
the relationship between IR and inflammation.  The first, presented in section 4, 
shows that disruption of pro-inflammatory cytokine signaling (TNF-R, IL1-R and 
TLR4 knockout animals) causes an improvement in insulin sensitivity.  
Specifically, ob/ob mice with TNF-R knocked-out have lower fasting glucose and 
plasma insulin levels, in addition to increased GLUT4 expression.  IL-1 receptor 
KO mice have improved glucose homeostasis and are somewhat protected from 
adipose tissue inflammation on HFD.  Also, they perform better on ITT and GTT 
compared to control animals.  When TLR4 receptor is knocked out, the HFD-fed 
mice display low adiposity, body weight and increased insulin sensitivity.  This 
phenotype has been attributed to a corresponding decrease in JNK and NF-κB 
activity.  The second type of animal study, presented in section 5, explains how 
drugs targeting inflammation can impact insulin sensitivity.  Inhibiting 
inflammation with a pharmacological intervention can help restore insulin 
sensitivity in animals.  Aspirin and sodium salicylate can improve glucose 
tolerance and insulin signaling in Zucker rats and ob/ob mice.  Mechanistically, 
this is achieved, in part, by increasing both tyrosine phosphorylation on the 
insulin receptor and phosphorylation of AKT.  A soluble TNF-R can improve 
glucose uptake in mice challenged with a dose of insulin.  Lastly, blocking IL-1β 
with a monoclonal antibody improves glycemic control in obese mice.  This data 
is very hopeful.  However, there are still questions that remain to be answered in 
animal studies. 
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 A few of the major areas where more animal research could prove 
informative are: where should drugs act (specific tissues, cell type, intra/extra 
cellular approach, where in signaling cascade), when should intervention take 
place (during specific metabolic events, before or during disease onset), and 
which anti-inflammatory drugs could work best (NSAIDs, steroids, proteins vs. 
small molecules) and what kind of therapeutic approach would be the most 
beneficial (partial vs. full inhibition, least side effects).       
The tissues where anti-inflammatory intervention may be most beneficial 
are adipose, pancreas, muscle and liver.  Inflammation in the adipose can cause 
recruitment of M1 macrophages and increased pro-inflammatory cytokine 
production. Adipose is the primary site of energy storage.  It is capable of 
secreting factors that contribute to IR, such as TNF-α and adipokines, like 
resistin.  Secretion can occur as the cell becomes stressed (i.e growth of lipid 
droplet causes hypertrophy).  Inside the pancreas, beta cells produce insulin.  
Insulin is the major regulator of glucose homeostasis.  Chronic inflammation can 
impair beta cell function, causing impaired insulin secretion [13, 91].  Muscle is 
the main site of glucose disposal and utilization.  The liver is the primary site of 
gluconeogenesis.  These two organs are critical for maintenance of proper 
metabolic function. When inflammation is chronic in these tissue types, the body 
could be at higher risk for becoming insulin resistant.  Therefore, it would be 
informative to design animal studies to conditionally knockout inflammatory 
signaling in only these organs.  These animals are generated by mating 
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genetically modified mice (i.e. TNF-α deficient) with another line expressing 
recombinase in the tissue (s) of interest.  The result is an animal with genetic 
modifications only in the tissues where recombinase is being expressed.  For 
example, dampening IL-1β expression in muscle could yield different results than 
the identical treatment in adipose, liver or the pancreas.  This study could help 
point out the most critical places where specific (by cytokine or pathway) anti-
inflammatory therapy could be useful. If successful, this approach could help limit 
unwanted side effects of anti-inflammatory therapy, such as compromised 
function of the immune system. These studies have the potential to help design 
drugs with limited toxicity and allow for a deeper understanding of inflammation-
induced IR in specific tissues. 
Another way to block pro-inflammatory cytokines only in the cell types 
desired, (adipose, muscle, liver and pancreatic beta cells) is by adding a 
targeting toggle to the inhibitor (antibody, decoy receptor, natural antagonist, etc) 
[26]. Then when the anti-inflammatory drug is administered, it only affects a 
chosen subset of cells.  This approach has been used to treat cancerous tumors 
for years.  One example is Trastuzumab Emtansine (T-DM1), developed to treat 
HER2-positive advanced breast cancer [109].  T-DM1 combines an anti-HER2 
mAb therapy with a cytotoxic microtubule inhibitory agent.  The goal of this 
design is to deliver drug only to HER2-over-expressing cells.  The advantages of 
this approach are the limited impact of cytotoxic agent on healthy cells and an 
improved therapeutic index.  One downside to this kind of therapy is the high cost 
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of development.  Also, the risk remains of unwanted effects, since the target 
receptor may be expressed on other cell types that have not yet been 
discovered.  In breast cancer trials, this approach has proven itself effective.  
According to the NEJM manuscript, T-DM1, “significantly prolonged progression-
free and overall survival with less cytotoxicity… in patients with HER-2 positive 
advanced breast cancer”.  This success can be used as a guide to design better 
drugs to treat IR.  Targeting the inflammatory component in and around relevant 
cell types is an approach that could be explored in animals. 
Muscle, liver, adipose and pancreatic beta cells all display their own 
unique surface proteins.  Those markers can be used to hone in on the specific 
tissues, with an anti-inflammatory attached for therapy.  For example, 
mononuclear murine skeletal muscle cells are Ly5.1+ and hepatic cells express 
glial fibrillary acidic protein (GFAP) [110, 111].  The hybrid molecule could be an 
anti-Ly5.1+ antibody fused to an NSAID. White adipose tissue expresses fatty 
acid binding protein-4 (FABP4) and pancreatic beta cells display diacylglycerol 
kinase beta (DGKB) and glycoprotein M6A (GPM6A) on their membrane surface 
[112, 113].  It would be interesting to compare the efficacy of targeted anti-
inflammatory therapy to controls (no targeting module) in animals with IR.   To 
see if the targeted therapy is more efficient, one could measure JNK and NF-κB 
inhibition coupled with an increase in glucose tolerance. 
 The first step in inflammation-induced IR is the congregation of activated 
immune cells in tissues (i.e. adipose) and their secretion of pro-inflammatory 
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cytokines [20]. This upstream event is a good place to attempt intervention, since 
targeting specific pro-inflammatory cytokines has shown modest success in 
animal and human trials.  M1-like macrophages, the pro-inflammatory variety, are 
an enticing cell type to go after to treat IR.  Leaving the M2-like macrophage 
population untouched could avoid dampening the innate immune response.  
GPR120 is a protein expressed primarily in M1-like macrophages [114].  By 
capitalizing on this difference between macrophage cell populations, treatment 
could be tailored to hit the M1’s only. This approach could be tested in animals to 
see if they become more insulin sensitive.  Another way to target M1 
macrophage infiltration, is by inhibiting macrophage chemotaxis.  The literature 
reports, “>90% of monocytes that migrate into obese adipose tissue become M1-
like ATMs, whereas M2-like ATMs may be derived from the proliferation of 
resident cells.”  Inhibiting chemotaxis could help inhibit the inflammation that 
occurs in adipose tissue.  This could be tested in animals by injecting 
fluorescently tagged monocytes, treating with an anti-chemotactic agent and then 
tracking the movement of the cells. If successful, it would be interesting to see if 
animals with fewer M1 macrophages in their adipose were less prone to 
developing IR, compared with controls.  Some examples of anti-chemotactic 
factors are peptide T or an antibody to monocytes chemotactic protein-1 (MCP-1) 
[20, 115].  In this case, there could be significant side effects of inhibiting 
chemotaxis systemically.  Therefore, in order to keep therapy safe it would be 
best to devise a plan to limit the effect to WAT chemotaxis. 
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 Another major question that needs to be addressed is which kind of anti-
inflammatory drug is best to treat IR.  The choices include small molecule drugs 
like NSAIDs and steroids and large protein therapeutics, such as monoclonal 
antibodies.  Although studies in animals cannot accurately predict the therapeutic 
index in humans, they may help deduce which type of anti-inflammatory drug is 
most effective.  A head to head study comparing the following drugs, and their 
impact on insulin sensitivity is a straight-forward method for finding the best 
candidates to pursue:  NSAIDs (i.e. salsalate), glucocorticoids, anti-
cytokine/receptor antibodies (i.e. Embel, Etenercept), NF-κB inhibitors (i.e. MS-
417) and JNK inhibitors (i.e. GLP-1) and antioxidants [89].  By using a panel with 
a wide variety of anti-inflammatory approaches, investigators may uncover the 
most hopeful strategies and avoid wasting time on the more ineffective ones.  It 
is wonderful that there are so many anti-inflammatory drugs available, however, 
work needs to be done in animals to figure out which ones will improve insulin 
sensitivity.  
 New research on the inflammasome provides a variety of opportunities for 
intervention that could be tested in animals.  Inhibiting inflammasome function 
prior to caspase-1 processing of IL-1β and release from the cell would decrease 
the concentration of circulating pro-inflammatory factors.  For example, 
therapeutically blocking ASC (apoptosis-associated speck-like protein) would 
cause the inflammasome to become inactivated.  ASC is the essential adaptor 
protein linking the interaction between Nlrp3 and caspase-1.  Without the 
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interaction of Nlrp3 and caspase-1, the inflammasome is incapable of processing 
precursor IL-1β into its’ mature form. This is due to the fact that caspase-1 is 
activated through this interaction [32].  Using a biologic or small molecule drug to 
penetrate the cell and act on the inflammasome in the cytosol could prove 
beneficial.  This field of research is quite novel.  Animal studies aimed at 
knocking out/down inflammasome function may provide a new approach to 
treating metabolic dysfunction related to insulin resistance. 
 
B.  What kinds of human trials could safely and effectively prove anti-
inflammatory drugs are worth prescribing to treat insulin resistance? 
 
A few well-designed trials could build a convincing case for prescribing 
anti-inflammatory drugs for IR and MetS.  By using currently available drugs, the 
strategy can be tested quickly, and without high drug development costs.  The 
field of ‘meta-inflammation’, the chronic inflammation associated with metabolic 
disease, is still new.  However, there is enough data available in the literature to 
choose appropriate biomarkers to track the success or failure of a clinical trial of 
this kind.   
 The first step in organizing a safe and effective clinical trial is choosing the 
correct study population.  The individuals should be insulin resistant, glucose 
intolerant, have heightened plasma concentrations of CRP, TNF-α, IL-1β and 
HbA1c, and display M1-macrophage infiltration into the WAT.  Pre-screening for 
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these individuals ensures that the subjects show markers for chronic 
inflammation as well as insulin resistance.  Using appropriate biomarkers when 
identifying and choosing the study population will help find those individuals most 
likely to respond to this therapy. It is crucial to obtain baseline readings for these 
markers to compare them with data collected during and after anti-inflammatory 
therapy.  BMI should not be used to choose the participants, since some 
individuals with a high BMI are insulin sensitive and some with a low BMI are 
insulin resistant [116].  In addition, the study should exclude anyone currently 
fighting an infection, such as people with tuberculosis or cancer.   
 The safest way to gauge efficacy of anti-inflammatory drugs for IR in 
humans is by first testing drugs that are already on the market for other 
indications.  It would be wise to start off testing those drugs with the best safety 
profiles and least side effects.  The therapeutics include biologics and small 
molecule drugs for RA, Crohn’s Disease or other inflammatory conditions.  Since 
marketed drugs need to pass through rigorous Phase I, II and III clinical testing in 
order to get approval from the FDA, this approach avoids some of the risks 
associated with early phase drugs.  Phase I trials are used to assess a drugs’ 
safety profile, by revealing adverse events in healthy individuals.  Although these 
drugs have already been tested, it is prudent to re-evaluate the potential for 
toxicity, since the IR study population may have physiological differences than 
people with RA.  After safety has been established, then a trial should be run with 
a broad dose escalation to zone in on the correct therapeutic index.  This kind of 
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study should reveal the safest and most efficacious concentration and dosing 
regimen for drugs already available. 
 Only modest success has been achieved using a single anti-inflammatory 
drug to treat IR in humans.  Therefore, combination therapy may be a more 
effective approach.  For example, dosing with Anakinra (to block IL-1β) and 
Etanercept (to block TNF-α) together could have an additive effect to drive down 
inflammation and improve insulin sensitivity.   Alternatively, combining the small 
molecule drug Salsalate (to decrease NF-κB activity) with Peptide T (an anti-
chemotactic agent) may provide a more robust response.  Mixing and matching 
drug combinations allows researchers a chance to block more than one pathway 
simultaneously.  This has the possibility of being more efficacious than single 
drug therapy. IR is a complex disease that affects a variety of tissues and may 
have built-in signaling redundancies. 
 In order to get a better read on whether or not anti-inflammatory drugs can 
and should be used to treat IR, larger and longer trials need to be conducted.  
The clinical trial data collected to this point is composed of relatively small 
cohorts.  Future trials should include more participants, representing the wide 
variety of people with IR.  For example, the study should include: men and 
women, a variety of ethnic backgrounds, different lifestyle choices (exercise, 
occupations, diets, etc.), and a wide range of BMIs.  Also, the study should last 
for months, or even years (given drug safety remains intact).  Since the 
inflammation associated with IR is chronic, treating with an anti-inflammatory 
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over time could reduce inflammation, and keep it down, thereby restoring insulin 
sensitivity.  These larger, longer trials should be run in a double-blind fashion in 
order to avoid bias.  The data collected from a thorough clinical investigation of 
this kind would help support or reject the validity of this approach to treat IR.  
 Another trial design that could clarify this thesis is treating pre-diabetics 
with daily salsalate to see if this delays or stops progression to full blown T2DM. 
The participants in this study should have increased circulating inflammatory 
markers, higher than normal blood glucose levels, increased HbA1c, and 
impaired glucose tolerance [8].  However, they remain insulin sensitive and are 
otherwise asymptomatic.  These individuals are considered at high risk for 
developing T2DM.   By following two evenly matched cohorts over time (one 
group on salsalate “preventative” therapy and another taking a placebo), the trial 
could reveal if an anti-inflammatory is capable of interfering with the progression 
of disease.  Since the people in this study feel healthy, it is critical to treat them 
conservatively.  Therefore, low dose salsalate is a good candidate to ensure few, 
or no, side effects.  This is a similar therapeutic approach as taking a daily aspirin 
to lower risk of heart attack.  Daily aspirin therapy is not indicated for everyone, 
since it carries risks, such as internal bleeding.  However, many doctors 
recommend this preventative approach for people who have already had a heart 
attack or stroke (or other predisposing condition), in order to reduce risk of 
another cardiac event [117].  According to the American Diabetes Association 
website, “one major study, the Diabetes Prevention Program, showed about 11% 
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of people with pre-diabetes developed type 2 diabetes each year during the 
average three years of follow-up.  Other studies showed that many people with 
pre-diabetes develop type 2 diabetes in 10 years” [8].  Given this data, it seems 
reasonable to take an active approach in treating pre-diabetics.  
 The endpoints for these human trials would involve two aims.  First, and 
most importantly, measures of IR would be evaluated.  Insulin tolerance testing, 
glucose tolerance testing, fasting glucose concentration, and HbA1c levels would 
be tracked before, during and after treatment.  Second, the investigation should 
quantify the level of overall inflammation in the body (blood concentration of TNF-
α, IL-1β and CRP) as well as in adipose tissue using histology for M1-like 
macrophage infiltration.    
 
C.  Conclusion 
 
1.  There is an inflammatory component to MetS   
 
The discovery of the link between MetS and inflammation was made 
relatively recently.  This field of research is helping to provide greater insight into 
MetS’ etiology and progression.  For instance, pro-inflammatory cytokines can 
reduce insulin sensitivity and decrease GLUT4 activity.  Macrophages infiltrate 
adipose tissue, as the adipocytes swell with a bulging lipid load. Chronic 
inflammation stimulates JNK and NF-κB signaling, which turns on expression of 
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pro-inflammatory cytokines.  Also, the inflammasome, whose activity is fueled by 
the innate immune system’s response to foreign substances, stress signals, and 
cell damage, amps up expression and release of IL-1β, leading to the release of 
other pro-inflammatory cytokines.  These reduce insulin signaling and GLUT4 
transport, promoting insulin resistance indicative of the cross-talk between 
immune and metabolic processes. 
 
2. There are well known molecules to target 
 
 Many ligands (i.e. pro-inflammatory cytokines and FFAs), receptors, and 
signaling pathways are activated during inflammation.  The players involved are 
well-researched, as they have been targeted to treat inflammatory diseases for 
many years.  Inflammation has historically been a major problem for our species, 
and a lot of time and effort has gone into its’ research. For example, TNF-α, IL-
1β, TNF-R, IL-1R, JNK and NF-κB have all been studied extensively, in vitro and 
in vivo.  Their pathways provide ample opportunities for therapeutic target 
design. 
  
3. There are clinically approved drugs that might be retargeted to obesity and 
MetS 
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 Plenty of drugs exist to treat inflammation currently.  Some of these 
therapeutics are even available without a prescription, due to their effectiveness 
and safety profiles (i.e. aspirin).  Also, there are many protein therapeutics 
designed to block inflammatory diseases which have already gained approval 
from the F.D.A..  These newer therapies are much more specific.  Also, they are 
very expensive to develop and produce.  These drugs that were developed as 
anti-inflammatories, could potentially serve a dual purpose by testing them to 
treat MetS.  This approach cuts costs and time significantly by using resources 
that are already available.  Testing available anti-inflammatory drugs on people 
with MetS could help alleviate this growing health threat. 
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